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1. INTRODUCTION 
 
1.1 EPIGENETICS 
The genome contains information in two forms, genetic and epigenetic. The genetic 
information is stored in each cell in the form of DNA as genetic code, that provides the 
blueprint for the manufacture of all the proteins necessary to create a living thing, while the 
epigenetic information provides instructions on how, where, and when the genetic information 
should be used. Epigenetic mechanisms allow genetically identical cells to achieve diverse 
stable phenotypes by controlling the transcriptional availability of various parts of the genome 
through differential chromatin marking and packaging: ensuring that genes are turned on at the 
proper time is as important as ensuring that they are turned off when not needed [Shen and 
Laird, 2013].  
The term epigenetics (literally 'over' or 'upon' genetics) was originally defined, in the early 
1940s, to describe the events that could not be wholly explained by traditional genetics. Conrad 
Waddington (1905-1975) defined epigenetics as "the branch of biology which studies the 
causal interactions between genes and their products, which bring the phenotype into being", 
and this concept was used to explain why genetic variations sometimes did not lead to 
phenotypic variations and how genes might interact with their environment to yield a 
phenotype [Waddington, 2012]. Waddington’s definition initially referred to the role of 
epigenetics in embryonic development; however, the definition of epigenetics has evolved over 
time as it is implicated in a wide variety of biological processes. The current definition of 
epigenetics is “the study of changes in gene function that are mitotically and/or meiotically 
heritable and that do not entail a change in DNA sequence”; most of these heritable changes 
are established during differentiation and are stably maintained through multiple cycles of cell 
division. This heritability of gene expression patterns is mediated by epigenetic modifications, 
including methylation of the DNA bases, post-translational modifications of histone proteins as 
well as the positioning of nucleosomes along the DNA and the micro-RNAs. The complement 
of these modifications, collectively referred to as the epigenome, provides a mechanism for 
cellular diversity by regulating what genetic information can be accessed by the transcriptional 
machinery [Sharma et al., 2010]. 
 
1.2 DNA METHYLATION 
The major form of epigenetic information in mammalian cells is DNA methylation. It consists 
in the reversible covalent addition of a methyl group (-CH3) predominantly at the five position 
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of the cytosine pyrimidine ring, thereby creating 5-methylcytosine (5mC). 5mC accounts for 
the 3% of total cytosine bases in the DNA. In mammals, this reaction almost exclusively 
occurs in cytosines located 5 prime to the guanine base, commonly annotated as CpG 
dinucleotides, where the intervening ‘p’ represents the phosphodiester bond linking cytosine- 
and guanine-containing nucleotides [Rottach et al., 2009]. CG dinucleotides are infrequent in 
the genome, except at short DNA sequences termed “CpG islands”, that often colocalize with 
gene promoters and regulatory regions. For this reason, DNA methylation has been 
functionally linked mainly to the control of gene expression [Li and Zhang; 2014]. 
 
1.3 ESTABLISHMENT OF THE DNA METHYLATION PATTERN  
In the life cycle of an individual, the genome undergoes extensive reprogramming of 
methylation pattern during early development. In mammals, following fertilization, the levels 
of cytosine methylation globally decrease from the first cleavage stages up to the early 
blastocyst, before being reacquired during and after implantation. Immunofluorescence studies 
have shown that this global demethylation occurs asymmetrically on both parental genomes: 
the paternal DNA rapidly looses 5mC signal in the zygote before DNA replication, probably 
through a process of active demethylation, whereas the maternal DNA is thought to lose the 
methylation pattern over several cell divisions by a replication-dependent passive 
demethylation [Saitou et al., 2012]. This was confirmed by the observation that 
preimplantation blastocysts have a globally demethylated genome and one of the possible 
reasons is that it may facilitate the activation of the pluripotency program in the embryo. 
Exceptions are imprinting control regions (ICRs), that faithfully maintain allele-specific 
epigenetic pattern after fertilization and direct the monoallelic expression of clusters of 
imprinted genes in embryonic development. All ICRs identified so far are also known as 
differentially DNA methylated regions (DMRs) on the two parental chromosomes, mainly the 
maternal, thus indicating that the oocyte genome is more prone to transmit functional gene 
methylation states to the embryo than the paternal genome [Radford et al., 2011].  
In postimplantation embryos, new patterns of DNA methylation are re-established. After 
implantation, the cells of the epiblast becomes the source of all embryonic lineages, including 
the primordial germ cells (PGCs). PGCs undergo a second wave of epigenetic reprogramming 
that is completed by embryonic day 13.5 and is characterized by exchange of histone variants, 
loss of histone modifications and global erasure of DNA methylation at all gene loci during 
their proliferation and migration. These kinetics of demethylation appear to be complex and 
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might reflect the use of a combination of passive and active processes to achieve full 
demethylation in PGCs. When epigenetic reprogramming is completed, PGCs enter meiotic 
prophase in females and mitotic arrest in males [Auclair et al., 2012]. 
 
1.4 DISTRIBUTION  OF DNA METHYLATION SITES 
The frequency of CpG dinucleotides in humans is 1%, only the 21% of the expected number 
based on the GC content in the human genome; this underrepresentation is due to the inherent 
mutability of methylated cytosine. The product of cytosine deamination, uracil, is readily 
recognized as aberrant by the base excision repair machinery and corrected: the enzymes TDG 
(thymine DNA glycosylase) and MBD4 (methyl-CpG domain protein 4) have been reported to 
selectively remove thymine from a T:G mismatch in the context of CpG dinucleotides. In 
contrast, the deamination product of methylated cytosine is thymine, leading to a potential C to 
T transition in the next round of replication. Consequently, methylated CpGs in the germ line 
are likely to be lost over time [Weber et al., 2007].  
This low number of overall CpG dinucleotides is not uniformly distributed along the genome: 
as mentioned before, the human DNA is globally characterized  by unusually dense clusters of 
CpG dinucleotides called “CpG islands” (CGIs). These regions are defined as usually of 200 
bp-2 kb in length and characterized by higher density of G+C bases than the rest of the genome 
(at least 55%), a ratio observed/expected of CpG frequency of at least 0.6, and a consequent 
little CpG depletion [Illingworth et al., 2008]. There are about 29,000 CpG islands in the 
human genome, and the majority of gene promoters, roughly 60%, reside within CpG islands 
and are characterized by frequent absence of DNA methylation: in particular, the promoters for 
housekeeping genes are often embedded in CpG islands, as well as a proportion of tissue-
specific genes, tumor suppressor and developmental regulator genes. In contrast, the 80% of 
CpG dinucleotides located outside of CpG islands of mammalians are heavily methylated and 
can be found in promoters on the inactive X chromosome, in one allele of imprinted genes and 
in gene bodies, as well as in and nonrepetitive intergenic sequences, in satellite DNA and 
within repetitive elements. This distribution pattern of methylated CpGs in human genome is 
not random: DNA methylation plays a crucial role in the regulation of gene expression, and, 
basically, its presence is associated with stable gene silencing [Meng et al., 2015]. 
 
1.5 IMPACT OF DNA METHYLATION ON GENE TRASCRIPTION 
In general, gene expression and DNA methylation are inversely correlated. In the cell, DNA 
methylation exerts its biological function of transcription repressor in at least two ways.  
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Interference with Transcription Factor Binding. The presence of methyl groups bound to the 
cytosines can physically impede the binding of transcription factors to the gene promoter and, 
hence, directly interfere with gene activation. A number of transcription factors recognize GC-
rich sequence motifs that can contain CpG sequences: several of these are unable to bind DNA 
when the CpG sequence is methylated [Li and Zhang, 2013]. A recent study revealed that 
DNA-binding factors can also shape DNA methylation patterns: whole genome bisulphite 
sequencing analysis of embryonic cells in mice revealed the existence of low-methylated 
regions (LMRs) at CpG-poor distal regulatory regions. LMRs are occupied by transcription 
factors and their binding is both necessary and sufficient to generate LMRs, indicating that 
transcription factors can vice-versa influence local DNA methylation [Stadler et al., 2011]. 
Recruitment of Methyl-CpG Binding Proteins and Repressor Complexes. The second mode of 
repression is opposite to the first as it involves proteins that are attracted to rather than repelled 
by methyl-CpG. These proteins, called methyl-CpG-binding domain proteins (MBDs) are 
characterized by a DNA-binding motifs able to specifically recognize and bind only 
methylated CpGs. In addition, the MBD proteins can in turns recruit co-repressor complexes 
such as histone deacetylases, histone lysine methyltransferase or other larger chromatin 
remodeling protein, leading to the formation of silenced states of chromatin that ensures a 
stable repression of gene transcription [Li and Zhang, 2013].  
More recent researches have identified a new class of protein characterized by the CXXC 
domain, that can specifically recognize unmethylated CGs and can target other proteins or 
histone demethylases to unmethylated CpG islands. It has been suggested that this recruitment 
might help to maintain an unmethylated state similar to that seen with classic transcription 
factors, but evidences for this model are still missing [Shubeler, 2015].  
 
1.6 FUNCTIONS IN NORMAL DEVELOPMENT 
DNA methylation is essential for regulating several cellular processes during normal 
mammalian development, including the silencing of retrotransposon elements, the tissue-
specific gene expression, the genomic imprinting, and the X chromosome inactivation.  
Silencing of transposable elements. Mobile DNAs, also known as transposons or “jumping 
genes”, are widespread in nature and comprise an estimated 45% of the human genome. These 
sequences consist in intragenomic repeated and endoparasitic elements dispersed throughout 
the genome and are divided in two different classes: DNA transposons are sequences which 
move by a “cut-and-paste” mechanism via an element-encoded transposase, while 
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retrotransposons are RNA transposons that use a “copy-and-paste” mode of moving in 
genomes through an RNA intermediate. 
A substantial fraction of the human genome (> 30%), is derived directly or indirectly from 
LINE-1 retrotransposon activity. If expressed, these elements are potentially harmful as their 
replication and insertion can lead to chromosomal instability, translocations, gene disruption 
and DNA mutations. To prevent their movement around the genome these mobile elements 
need to be silenced completely and stably [Hancks and Kazazian, 2012]. The vast majority of 
these elements are inactivated by mutations acquired over time as the result of the deamination 
of 5mC, by rearrangements or heavily silenced by bulk hypermethylation. Despite the presence 
of more than 500,000 copies in the human genome, most of these elements are inactive, with 
only a subset, an estimated 80–100 elements, currently active. Full-length human L1 is ~6.0 
kb, contains an internal promoter located in the 5’-untranslated region (UTR) and two non-
overlapping open-reading frames (ORF1 and ORF2); both ORFs are required for L1 
retrotransposition, since ORF1 encodes a 40 kDa protein that contains a coiled-coiled domain, 
a non-canonical RNA recognition motif domain and a basic C-terminal domain, while ORF2 
encodes a 150 kDa protein that contains endonuclease and reverse transcriptase activity 
[Moore et al., 2013].  
Apart from LINE-1, also SINE (short interspersed elements) elements have been discovered, of 
which the most abundant class is represented by the Alu insertional elements. Alu elements are 
dimeric sequences approximately 300 bp in length derived from the 7SL RNA gene. These 
sequences contain a bipartite RNA pol III promoter, a central poly A tract, a 3' poly A tail, 
numerous CpG islands and are bracketed by short direct repeats. An estimated 500,000-
1,000,000 units are dispersed throughout the human haploid genome and their retroposition 
activity is determined by both internal and flanking regulatory elements as well as distant 
genes affecting transcription or transcript stability. As for LINE-1, Alu trasposable activity is 
turned-off by bulk methylation [Rodriguez et al., 2008]. 
Dosage compensation. In female mammalian development, X-chromosome inactivation (XCI) 
occurs during early embryogenesis to transcriptionally silence one of the pair of ~156-Mb X 
chromosomes, thereby achieving dosage compensation with males who have a single X 
chromosome. The X-inactivation process converts an X chromosome (Xi) from active 
euchromatin into transcriptionally silent and highly condensed heterochromatin through a 
series of events that include the coating of the X chromosome by Xist RNA, DNA methylation 
and histone modification. Several studies have shown that DNA methylation of the Xi plays a 
central role in the maintenance of its inactive state. While the active X (Xa) and Xi have very 
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similar global levels of methylation, CpG islands on the Xi have a tendency to be methylated, 
while those located on the Xa are unmethylated. In contrast, CpG dinucleotides of genes 
escaping from XCI often remain unmethylated on both the Xi and Xa [Cotton et al., 2015].  
Genomic imprinting. Genomic imprinting is a process causing the mono-allelic expression of a 
specific subset of autosomic genes in a parental origin specific manner — i.e., genes that are 
expressed either from the paternally inherited chromosome or from the maternally inherited 
chromosome (paternal allele and maternal allele henceforth) are imprinted. Today, over 100 
imprinted genes have been identified, and are usually organized in clusters where they are 
controlled by a unique imprinted control region rich in CpGs, that are methylated in one of the 
two strands, thus leading to the transcriptional silencing of the methylated allele. The 
acquisition of methylation at ICRs occurs during the germ cell development through a de novo 
process with a small number of ICRs becoming methylated in intergenic regions of sperm 
DNA and the majority acquiring methylation at promoter sequences of oocyte genome. Several 
syndromes and complex deseases such as cancer are associated with deletions or aberrations in 
DNA methylation of ICRs [Adalsteinsson and Ferguson-Smith, 2014].  
 
1.7 THE DNA METHYLATION MACHINERY 
Epigenetic modifications concerning methylation are written, erased, read, and regulated by a 
set of specific proteins, that collectively form the DNA methylation machinery. 
Writers of DNA methylation pattern. The reaction of addition of the methyl group to the 
cytosines is catalyzed by the enzymes belonging to the family of the DNA methyltransferases 
(DNMTs), that use the S-adenosyl-L-methionine (SAM, also known as AdoMet) as the methyl 
donor. The methyl group of AdoMet is bound to a sulfonium ion that thermodynamically 
destabilizes the molecule and makes the relatively inert methylthiol of the methionine part very 
reactive toward activated carbon atoms. This reaction involves the DNMT DNA binding 
domain, flipping the target cytosine out of the double helix, with the consequent formation of a 
transient covalent complex with the cytosine residue. The DNMT domain adds a cysteine 
thiolate to the 6-carbon of the substrate cytosine, followed by transfer of the methyl group to 
the 5-carbon [Daniel et al., 2011]. 
DNA methyltransferases are the family of enzymes responsible for methylation pattern 
acquisition during gametogenesis, embryogenesis, and somatic tissue development. To date, 
four active members of this family have been identified in mammals: DNMT1, DNMT3a, 
DNMT3b and DNMT3L. DNMT1 is often referred to as maintenance methyltransferase, 
because it is believed to be the primary enzyme responsible for the maintenance of methylation 
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during replication by copying the methylation pattern of the parent DNA strand onto the newly 
synthesized strand through its peculiar preference for hemimethylated templates. 
Consequently, it passes the epigenetic information over cell divisions. DNMT1 is particularly 
present at high concentrations in dividing cells, always located in replication foci; it also 
operates with its methylation co-factor UHRF1 in protein complexes that constitute an 
enzymatic platform and contains an N-terminal region that is associated with various 
chromatin-associated proteins, including the de novo methyltransferases, histone-modifying 
enzymes and MeCPs [Meng et al., 2015].  
DNMT3a and DNMT3b are responsible for de novo DNA methylation, targeting cytosines of 
previously unmethylated CpG dinucleotides as well as working with DNMT1 to ensure 
propagation of methylation patterns during DNA replication. Particularly, these enzymes have 
an equal preference for hemimethylated and unmethylated DNA, essential for their roles in de 
novo methylation of the genome during development and for newly integrated retroviral 
sequences [Walton et al., 2011]. Following the first wave of genome-wide demethylation in the 
preimplantation embryo, DNMT3a and DNMT3b are highly expressed at implantation and re-
establish a bimodal methylation pattern that effects more than 80% of the genome. Genetic and 
functional analyses carried on in mice indicate that Dnmt3a and Dnmt3b have non-overlapping 
functions during development: accordingly, Dnmt3a is necessary for maternal imprinting at 
differentially methylated regions, while Dnmt3b is required for methylation of pericentromeric 
repeats and CGIs on inactive X chromosome [Takeshima et al., 2006]. Of special interest is 
DNMT2 (also known as TRDMT1), which has reportedly only weak DNA methylation ability 
in vitro and appears to have the potential to methylate RNA instead of DNA. Finally, 
DNMT3L (DNMT3-like) has no catalytic activity itself: it stimulates the de novo 
methyltransferase activity of Dnmt3a or Dnmt3b through physical interaction by increasing 
their ability to bind to the methyl group donor, the S-adenosyl-L-methionine [Meng et al., 
2015].  
Strong and continual cooperation between different methyltransferase enzymes is needed for 
the maintenance of DNA methylation, especially in repeats and imprinted genes. Although this 
classical proposal based on a maintenance methyltransferase and on two de novo DNMTs has 
been supported for many years, more recent experimental observations that do not fit with this 
simple model have been accumulating. The observation that DNMT1 alone is incapable of 
perfect maintenance methylation and the localization of the DNMT3a and DNMT3b enzymes 
to specific chromatin regions containing methylated DNA has led to the proposal of a revised 
model. It predicts that Dnmt1 maintains the bulk of DNA methylation in dividing cells but it is 
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also able to perform error corrections, thus having a role in de novo methylation of genomic 
sequences. Dnmt3a and Dnmt3b, apart from their role in de novo methyltransferase activity, 
appear to be also involved in the maintenance of the DNA methylation pattern during each 
cellular replication [Jones and Liang, 2009; Walton et al., 2011].  
Readers of the DNA methylation pattern. As mentioned before, the “written” methylation 
marks at CpG dinucleotides can be specifically recognised by various Methyl-CpG Binding 
Proteins (MBPs), which may specifically recognise and subsequently interpret the established 
methylated CpG marks by recruiting chromatin modifiers and remodeling complexes to 
establish a repressive pattern of gene expression. Almost all MBPs have been demonstrated to 
associate also with transcriptional repressors, implying an additional layer of regulation 
between DNA methylation and transcription. All the methyl-CpG binding proteins share 
binding specificity for symmetrical 5meCpG dinucleotides, although they retain differences in 
DNA binding specificity and unique roles [Zou et al., 2012].  
The various MBPs could be divided in three structural families: the MBDs, the zinc finger and 
the SRA family. The MBD protein family consists of eleven known protein, including MeCP2, 
MBD1, MBD2, MBD4, SETDB1, SEDTB2, BAZ2A and BAZ2B, that specifically recognise 
5-methyl-CpG dinucleotides via novel methyl-CpG-binding domain (MBD). The 70–85-amino 
acid MBD domain has the ability to bind single symmetrically methylated CpG dinucleotides. 
An exception is represented by MBD3, that is the only family member that does not bind 
specifically to methylated DNA but can bind to unmethylated DNA and has been reported to 
bind to 5-hydroxymethylated cytosines [Meng et al., 2015].  
In addition to the MBD domain, MBD family members contain several differing domains that 
reflect their respective roles. Most family members contain a transcriptional repression domain 
(TRD) that mediates interactions with protein partners. Other family members possess unique 
domains such a glycosylase domain (MBD4) or unmethylated-CpG-binding zinc finger (CxxC) 
domain (MBD1) [Du et al., 2015]. The second KAISO family comprises structurally unrelated 
zinc-finger proteins, KAISO and its two close paralogs: ZBTB4 and ZBTB38. These proteins 
have been shown to bind to methylated DNA through zinc-finger motifs, but can also bind a 
non-methylated consensus. The third family includes two 5meCpG-binding ubiquitin-like 
proteins UHRF1 and UHRF2, which recognise methylated DNA via SET and RING finger-
associated (SRA) domains. Specifically, UHRF1 is an essential protein that binds 
hemimethylated DNA and acts in conjunction with DNMT1 to facilitate maintenance DNA 
methylation; in the absence of UHRF1, there is a precipitous loss of DNA methylation [Buck-
Koehntop and Defossez, 2013]. 
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Erasers of DNA methylation pattern. Many developmental biologists have described the waves 
of genome-wide DNA demethylation occurring in the germline and in early embryogenesis, 
however, the process by which DNA methylation is erased has been elusive. Recent 
discoveries have established that the DNA demethylation process can be achieved through both 
a passive and an active mechanism: passive loss of DNA methylation refers to the failure of the 
maintenance of the methylation pattern during successive rounds of DNA replication either in 
the absence of DNMT1 or because of its inhibition, while active DNA demethylation refers to 
an enzymatic process that results in the removal of the methyl-group from 5mC [Wu and 
Zhang, 2014]. During preimplantation development the 5mC levels of the maternal genome 
went through a replication-dependent dilution process (i.e., passive demethylation); in contrast, 
the 5mC levels of the paternal genome dramatically decrease a few hours after. Given that no 
DNA replication occurs during this period, the loss of 5mC in the paternal genome is 
considered active. Another place where global loss of 5mC is observed is in the primordial 
germ cells (PGCs), specifically by the time they arrive at the genital ridge. Because PGCs have 
undergone several cell cycles in the presence of DNMT1 during this process, the loss of the 
epigenetic marks is likely to be active [Wu and Zhang, 2014]. Active DNA demethylation has 
also been reported in somatic cells in a locus-specific manner as a physiological process, and 
because no DNA replication takes place in the processes described above, active DNA 
demethylation is believed to be responsible for the loss of DNA methylation. The mechanism 
through which active DNA demethylation takes place has been elucidated after the 
identification of 5-hydroxymethylcytosine (5hmC) as a bona fide base of mammalian genomic 
DNA and the demonstration that the ten–eleven translocation (TET) protein family is 
responsible for the conversion of 5mC to 5hmC. It was experimentally shown both in vitro and 
in vivo that TET-mediated 5mC oxidation should be able to proceed further to generate 5-
formylcytosine (5fC) and, more limited, 5-carboxylcytosine (5caC).  
The TET enzyme family comprises three cytosine dioxygenases, TET1 and its two 
dioxygenase paralogues TET2 and TET3. C-terminal catalytic domains of TET proteins 
contain an indispensable cysteine-rich region adjacent to their DSBH domain, that is able to 
oxidise the 5-methyl group on thymine (T) to 5-hydroxymethyluracil (5hmU). In addition, 
TET1 and TET3 carry a cysteine–X–X–cysteine (CXXC) domain at the N-terminus that 
strongly binds to unmethylated DNA. The conversion of 5mC to 5hmC probably leads to loss 
of maintenance of existing DNA methylation patterns given that 5hmC is not recognized by 
DNMT1 during DNA replication leading to passive DNA demethylation during cell division. 
In addition, the 5mC oxidation products 5fC and 5caC may serve as intermediates for active 
 13
DNA demethylation as both can be cleaved by the thymine-DNA glycosylase (TDG). Tet-
mediated 5mC oxidation followed by TDG-mediated excision of 5fC/5caC and base excision 
repair (BER) might be one of the pathways for active DNA demethylation [Pastor et al., 2013].  
The substitution of 5mC residues with 5hmC may be translated in the inhibition of the 
recruitment of the classic 5mC interpreter MeCPs, thus weakening subsequent transcriptional 
repression activities. in vitro studies showed that MeCP2 has a markedly reduced binding 
affinity for 5hmC in contrast to its strong binding affinity for 5mC. The less bound MeCP2 
may release the associated chromatin modifying enzymes, deregulating the repressive 
transcription environment [Meng et al., 2015].  
 
1.8 ABERRANT DNA MEHYLATION AND CANCER 
Gene function in cancer can be disrupted either through genetic alterations, which directly 
cause intragenic point mutations, allelic loss and deletions as well as amplifications and 
translocations, or epigenetic alterations, which alter the heritable state of gene expression. The 
epigenetic pattern present in normal cells undergoes extensive distortion in cancer: cancer 
epigenome is characterized by global changes in DNA methylation and histone modification 
patterns as well as altered expression profiles of chromatin-modifying enzymes. These 
epigenetic changes, namely epimutations, result in global dysregulation of gene expression 
profiles leading to the development and progression of disease states [Peltomaki, 2012]. 
Epimutations can induce inappropriate silencing of tumor suppressor genes and/or activation of 
oncogenes independently or in conjunction with deleterious genetic mutations or deletions: for 
this reason, they could represent the second hit required for cancer initiation as proposed by 
Knudson in the “two-hit” hypothesis [Knudson, 1971]. 
Above all the epigenetic abnormalities in the cancer cell, aberrant DNA methylation is the 
most common molecular lesion. Aberrant DNA methylation is deeply involved both in cancer 
development and progression because DNA methylation pattern is inherited with a high 
fidelity in somatic cells. Once aberrant DNA methylation is induced, it is accurately 
transmitted to daughter cells after cell division: therefore, they are selected in a rapidly 
duplicating cancer cell population, thus conferring a growth advantage to tumoral cells 
[Sharma et al., 2010]. 
Historically, the first discovery of epigenetic alterations goes back to 1983, when global 
hypomethylation of the cancer genome was described, and  after a decade, site-specific CpG 
island hypermethylation within the promoter region of a tumor suppressor gene was 
demonstrated to cause its silencing. The CpG island methylator phenotype (CIMP), defined as 
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frequent methylation of multiple CGIs, was reported first in colorectal tumors in 1999 [Toyota 
et al., 1999] and thereafter extended in other types of cancers. More recently, mutations of 
epigenetic regulators, including those of DNMTs, TET and IDH have been revealed, and 
epigenetic drugs, such as DNA demethylating agents, have already become an option for 
cancer treatment [Hattori and Ushijima, 2014].  
 
1.8.1 GENE-SPECIFIC HYPERMETHYLATION  
Increased methylation level of the CpG islands in the promoter regions of tumor suppressor 
genes has been accepted as being a common feature of human cancer: in 1993, inactivation of 
the RB tumor-suppressor gene by DNA hypermethylation of CpG islands spanning its 
promoter region was reported as the first evidence in cases with retinoblastoma. Subsequently, 
aberrant DNA methylation of other tumor-suppressor genes, many of them being housekeeping 
genes, i.e. genes that need to be constitutively expressed and transcriptionally active 
throughout development and differentiation in all tissues, was also reported as a way of 
inactivation alternative to genetic alterations, thus contributing to tumor development and 
progression. Silencing of these genes by CpG promoter hypermethylation in cancer cells is 
known to affect a wide range of cellular processes and several cellular pathways: cell cycle 
(Rb, BRCA1, p16 INK4a, p15 INK4b), DNA repair (BRCA1, MGMT, MLH1), transcription 
factors (GATA-4, GATA-5, VHL), epigenetic enzymes (NSD1, RIZ1), receptors (CRBP1, 
ESR1, TSHR), signal transduction (APC, RASSF1A, WIF1), detoxification and carcinogen 
metabolism (GSTP), metastasis and cell invasion (CDH1, TIMP3), apoptosis (DAPK, TMS1, 
CASP8), and angiogenesis (THBS1). Furthermore, aberrant promoter hypermethylation can 
deregulate differentiation genes, i.e. genes that have to be expressed only in a time- and tissue-
dependent manner [Berdasco and Esteller, 2010]. In addition to direct inactivation of tumor 
suppressor genes, DNA hypermethylation can also silence additional classes of genes 
indirectly: hypermethylation-mediated inactivation of the transcription factor RUNX3 (runt-
related transcription factor 3) in esophageal and gastric cancer and of transcription factors 
GATA-4 and GATA-5 in colorectal and gastric cancers leads to inactivation of their 
downstream targets, as well as silencing of DNA repair genes (e.g. MLH1, BRCA1 etc.) 
enables cells to accumulate further genetic lesions leading to the rapid progression of cancer 
[Sharma et al., 2010].   
Several reports have characterized a specific spectrum of gene hypermethylation for different 
tumor types, defining a “DNA hypermethylome” for each type of cancer, a sort of “map” that 
is even maintained in long-established human cancer cell lines. Some tumors have an higher 
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methylation level of the known CpG islands than others: for example, the most 
hypermethylated tumor types are those of the gastrointestinal tract, while significantly less 
hypermethylation has been reported in other types such as ovarian tumors and sarcomas 
[Esteller, 2007]. While the ability of DNA hypermethylation to silence tumor suppressor genes 
in cancer is well established, how genes are targeted for this aberrant DNA methylation is still 
unclear, as it still unknown why certain regions are more susceptible to hypermethylation, 
whereas others remain unmethylated in different cancer types. Recent epigenome-wide 
analyses revealed that in cancer cells a very high number (from several hundreds to one 
thousand) of genes with promoter CGIs is hypermethylated; however, since most of such genes 
are not expressed or expressed at very low levels in normal cells, they are considered not as 
“driver genes”, which are causally involved in tumorigenesis, but as “passenger genes”, that 
accompany the transformation process but have no effect per se on the process of 
carcinogenesis [Kalari and Pfeifer, 2010].  
 
1.8.2 GLOBAL DNA HYPOMETHYLATION 
The hypothesis that the cancer cell genome undergoes a reduction of its 5mC content in 
comparison with the normal tissue has been firmly corroborated: genome-wide 
hypomethylation in general occurs at repetitive elements, retrotransposons, pericentromeric 
regions, introns and gene deserts.  
Hypomethylation has been identified specifically in repeated elements and endogenous viruses 
but this is not surprising, since these DNA elements are highly abundant and comprise most of 
the CpG islands that are normally methylated in healthy somatic tissues. Currently, it is 
thought that the major contribution of transposons demethylation to tumor development is their 
activation and translocation to other genomic regions, leading to genomic and chromosomal 
integrity destabilization [Ehrlich, 2009]. It was hypothesized that DNA hypomethylation could 
lead to the activation and expression of classical oncogenes, but evidence suggests a greater 
involvement in the activation of developmentally critical genes or genes associated with tumor 
invasion or metastasis. However, activation of such genes by hypomethylation is still 
controversial because some of them do not have CpG islands in their promoters [Hattori and 
Ushijima, 2014]. 
 
1.8.3 DETECTION OF ABERRANT DNA METHYLATION: DIFFERENT APPROACHES  
Many different techniques for DNA methylation determination exist, and choosing the most 
appropriate one largely depends on the nature and number of the samples, information 
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required, and costs. The three main approaches are: methylation-specific restriction enzyme 
digestion, affinity purification of methylated DNA and DNA bisulfite conversion. The DNA 
obtained is further subjected to molecular-genetic approaches, which are for single locus 
analysis based on PCR, whereas in the case of genome-wide assay they are based either on 
microarray technology, mass spectroscopy or next generation sequencing analysis [Han and 
Garcia, 2013; Paska and Hudler, 2015].  
Presently, bisulfite genomic sequencing is regarded as a gold-standard technology for detection 
of DNA methylation because it allows a qualitative, quantitative and efficient approach to 
identify 5mCs at single base-pair resolution, as well as the analysis of methylation in repeat 
sequences and rare methylation variants [Li and Tollefsbol, 2011]. This method is based on the 
finding that the amination reactions of cytosine and 5-methylcytosine proceed with very 
different consequences after the treatment of sodium bisulfite. In this regard, non methylated 
cytosines in single-stranded DNA will be converted into uracil residues and recognized as 
thymine in subsequent PCR amplification and sequencing. 5mCs are immune to this 
conversion and remain as cytosines, allowing 5mCs to be distinguished from unmethylated 
cytosines. The DNA obtained is further subjected to molecular-genetic approaches, which are 
for single locus analysis based on PCR, whereas in the case of genome-wide interrogation they 
are based either on microarray technology, mass spectroscopy or next generation sequencing 
analysis [Paska and Hudler, 2015].  
 
1.8.4 HOW TO MEASURE GLOBAL DNA HYPOMETHYLATION 
There are many approaches which can be applied to the analysis of global DNA methylation. 
Currently, the gold standard methods for measurement of global methylation are based on the 
high performance liquid chromatography (HPLC) approach and its variants, as well as the 
Liquid Chromatography-Mass Spectrometry (LC-MS), that provide an absolute measurement 
of 5mC in samples of DNA by enzymatic hydrolysis of genomic DNA.  
As explained before, about 45% of the human genome is composed by repetitive regions, in 
which most of the CpG island methylation in the genome can be found. A substantial fraction 
of the human genome (> 30%), is derived directly or indirectly from LINE-1 retrotransposon, 
that is present in more than 500,000 copies. Also, Alu insertional elements have been 
discovered as highly abundant (500,000-1,000,000 units), dispersed in the genome and 
normally inactivated by heavy methylation [Hancks and Kazazian, 2012].  
For these reasons, one of the currently most reliable methods to evaluate global DNA 
methylation level is based on the assessment of the hypomethylation of these repetitive 
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sequences, that can serve as a reliable surrogate marker for global genomic DNA methylation 
[Lisanti et al., 2013]. Results from a recent study of global DNA methylation in murine cells 
and tissues showed a good correlation between LINE-1 promoter methylation level and total 5-
methylcytosine amount measured by LC-MS [Newman et al., 2012]. LINE-1 methylation 
levels are measurable through different technical approaches, each of them having specific 
advantages and disadvantages; however, due to its sensitivity, reproducibility, and the 
possibility to obtain quantitative methylation data, the bisulfite pyrosequencing in considered 
as one of the better choices for global DNA methylation analyses [Toraño et al., 2012].  
 
1.8.5 ABERRANT METHYLATION AS THERAPEUTIC TARGET 
Being a postsynthetic event, in proliferating cells DNA methylation is critically dependent on 
continued expression of DNA methyltransferases: this is an advantage for anticancer therapy 
since, unlike genetic changes, epigenetic changes may potentially be reverted by treatment 
with pharmacological agents. Inhibition of the expression of these enzymes would therefore 
result in progressive reduction in DNA methylation in newly divided cells, a phenomenon 
associated with reactivation of gene expression in hypomethylated cells [Issa and Kantarjian, 
2009]. Basically, DNA methylation inhibitors can be classified as nucleoside inhibitors and are 
represented by the 2′-deoxycytidine and its derivatives. 5-azacytidine and 5-aza-2′-
deoxycytidine are cytosine analogues that trap all DNA methyltransferases and target them for 
degradation. At low doses that do not inhibit proliferation, these drugs are effective 
hypomethylating agents and they have been proposed to have anti-tumour properties since they 
can inhibit tumour growth by specifically reversing the repression of tumour suppressor and 
cell cycle genes that are aberrantly methylated in tumour cells, and hence to have less side-
effects than non-specific conventional chemotherapy. An important implication is that, unlike 
conventional cytotoxic agents, it may be best to use such drugs at concentrations lower than the 
maximum tolerated dose [Ghoshal and Bai, 2007]. In addition these demethylating agents can 
be indirectly implicated in the anticancer therapy due to their potential to restore sensitivity to a 
range of chemotherapeutic agents including cisplatin, epirubicin and temozolomide [Fojo and 
Bates, 2003].  
 
1.9 DNA METHYLATION AS A POTENTIAL BIOMARKER IN CANCER  
A biomarkers is any naturally-occurring characteristics that can be objectively measured and 
evaluated as an indicator of normal biological processes, particular pathological processes or 
pharmacological response to a therapeutic intervention. An ideal biomarker must be able to 
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provide clinically-relevant information and be accurately measurable in multiple individuals, 
ideally across multiple populations. Biomarkers can be used at any stage of a disease and can 
be associated with its cause or latency (risk biomarkers), onset (diagnostic biomarkers), clinical 
course (prognostic biomarkers), response to treatment (predictive biomarkers), or  can also be 
associated with specific environments (exposure biomarkers). As almost all complex human 
diseases are caused by a mixture of genetic and environmental variation, biomarkers, 
especially those antecedent to disease, can be influenced by either of these factors and can also 
reflect the mechanisms by which exposure and disease are related [Mayeux, 2004]. The 
process of development of a new biomarker to be used in the clinical setting is a very long 
way, that can be summarized as follows: single studies provide potential biomarkers, which 
could be validated using an independent technique and replicated in an independent study, also 
known as external validation. Following the systematic review and/or meta-analysis of a large 
number of independent studies, they become candidate clinical biomarkers that can enter 
clinical trials. Once approved, they become proven clinical biomarkers, used in clinical 
practice [Mikeska and Craig, 2014].  
Throughout the process of carcinogenesis, there are many opportunities to identify cancer 
biomarkers, going from genetic to metabolic marks. The selected biomarkers must be specific, 
sensitive, and detectable in specimens obtained through minimally invasive procedures. 
Compared with molecular structures such as mRNA, miRNA and certain proteins, the use of 
DNA for the measurement of tumour markers can be more easily transferred from a research 
laboratory setting into routine diagnostics: it is a chemically stable molecule that can be readily 
amplifiable and easily detected; also, it can be stored and conserved for long periods of time 
[Mikeska and Craig, 2014].  
Regarding DNA methylation, methyl groups on cytosines are part of the covalent structure of 
the DNA: once methylation is acquired, it is in most cases chemically and biologically stable 
over time and can survive in most sample storage conditions. Almost any biological tissue 
sample or bodily fluid can be used for DNA methylation analysis, archival formalin-fixed 
paraffin-embedded (FFPE) samples included [Thirlwell et al., 2010]. Currently, DNA 
methylation appears as one of the most promising epigenetic biomarkers in cancer, not only for 
their stability and the relative ease in their detection: aberrant DNA methylation has a great 
potential to be used for as an early indication of neoplastic transformation, as indicated by 
reports in which aberrantly hypermethylated sites were detected in seemingly normal epithelia 
from people years before the overt development of cancer. Several DNA methylation markers 
have been evaluated in a variety of clinical specimens for cancer diagnosis, prognosis and 
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predictive information on therapeutic responses; in addition, DNA methylation can potentially 
be used as a biomarker to detect a tumor in the minimal residual disease [Jankowska et al, 
2015]. 
Apart from these advantages, DNA methylation-based biomarkers have some limitations, first 
the heterogeneity of clinical specimens, that may contain a mixture of components that bring 
different types of cells with its own methylation peculiarities. Even the adjacent sections of the 
same tumor may have slightly different composition and quantitatively different methylation 
patterns [Levenson, 2010]. Second, some DNA methylation changes are due to the exposure to 
environmental influences as well as to the aging, that should not to be misinterpreted as cancer 
predisposing alterations [Tost, 2009]. Third, the choice of region to be studied: the investigated 
locus should ideally be unmethylated in normal cases and methylated in cancer case, with 
methylation levels of a sample clearly classified as either normal or cancerous. In cancer, these 
ideal situations may be true for one region of a CpG island and not necessarily for another: 
multiple (epi)alleles are present, which differ in their pattern of methylated and unmethylated 
CpG positions [Mikeska et al., 2012].  
 
1.10 PROSTATE CANCER  
 
1.10.1 EPIDEMIOLOGY AND RISK FACTORS 
Prostate cancer is the most common cancer in men in Europe, accounting for about 25% of all 
non-skin tumors diagnosed in men [Ferlay et al., 2013]. It is also the most common cancer 
diagnosed in males in the United States: in 2014, the American Cancer Society estimated that 
233,000 patients would be diagnosed with prostate cancer and that prostate cancer alone would 
account for 27% of all new incident cases of cancer in men. Prostate cancer is also the second 
leading cause of cancer death in the US, accounting for 10% of all male cancer deaths [Siegel 
et al., 2014]. In Italy, 26% of all prevalent cases of male cancers (295,624) were patients with 
prostate cancer [Source: rapporto AIRTUM 2014]. The lifetime risk of being diagnosed with 
prostate cancer is approximately 16%, while the probability of dying is 3% [Source: SEER 
Cancer Statistics Reviews, 2010-2012 data]. 
Risk factors for prostate cancer include age, ethnicity, and family history: it is a disease that 
affects older men, with the median age at diagnosis of 67 years; furthermore, 59% of men older 
aged at least 80 years have histological evidences of latent disease [Bell et al., 2015]. 
Concerning family history, men with one or two first-degree relatives with this disease have a 
2-fold and a 4-fold, respectively, increased lifetime risk of developing prostate cancer 
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[Tabayoyong and Abouassaly, 2015]. Prostate cancer has a strong ethnic propensity: high 
incidences are documented in descendents of the Northern Europeans and African Americans, 
while other groups, including native Africans and Asians, are much less susceptible to the 
disease. A sort of North-South gradient distribution of prostate cancer incidence can also be 
noted, especially in Europe [Gunderson et al., 2011].  
 
1.10.2 ANATOMY AND GRADING 
The prostate gland is divided in three glandular regions: the peripheral (located posteriorly), 
the central and the transition zone (in the front of the gland surrounding the urethra), which 
respectively comprise ~70%, 25% and 5% of the prostatic glandular tissue. The peripheral 
zone is the site of origin of most carcinomas (70-80%), but some (~15%) arise in the 
transitional zone and, rarely, in the central zone. Morphological differences between tumors in 
these zones [Greene et al., 1991], as well as markers of poor prognosis at higher rates among 
peripheral zone cancers have been observed, suggesting different aggressiveness [Erbersdobler 
et al., 2002]. While cancers of the peripheral zone are typically diagnosed after biopsy 
procedures or radical prostatectomies, those arising from transitional tissue are incidentally 
discovered in men undergoing transurethral resection of the prostate (TURP), a non-curative 
procedure intended to treat urinary symptoms [Sinnot et al., 2015].  
The Gleason score for tumor-cell differentiation is the recommended methodology for prostate 
cancer grading. According to current international convention, the (modified) Gleason score of 
cancers detected in a prostate biopsy consists of the Gleason grade of the dominant (most 
extensive) carcinoma component plus the highest grade, regardless of its extent. To date, 
Gleason score represents the best-established prognostic indicator for prostate cancer 
progression [Heidenreich et al., 2014]. However, whether prostate cancers arise well-
differentiated and then progress to less differentiated forms or if Gleason grade is an early and 
largely unchanging feature of the tumor still remains to be clarified [Penney et al., 2013; 
Hussein et al., 2015]. 
 
1.10.3 PSA-BASED SCREENING AND RELATED ISSUES 
The introduction of PSA screening as an opportunistic screening for prostate cancer has had a 
profound impact on its incidence and mortality: in the US, a dramatic increase in prostate 
cancer incidence occurred with a peak in 1992, attributed to earlier detection of cases and to 
detection of cases that would never have been diagnosed or treated. After 1992 prostate cancer 
incidence declined until 1995, attributed to the cull effect resulting from the number of earlier 
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detected cases as a consequence of PSA screening. Moreover, prostate cancer mortality rates 
increased slowly between 1975 and the early 1990s with a peak in 1992, and has continued to 
decline steadily, such that today mortality rates are lower than that observed before the 
introduction of PSA screening [Tabayoyong and Abouassaly, 2015].  
PSA is a serine protease whose transcription is driven by androgens. It is producted by the 
prostatic epithelium and released into the seminal fluid. PSA levels in the blood are typically 
low, but can be increased owing to disruption of normal prostatic architecture, which occurs 
with malignant processes such as cancer but also with benign processes [Lilja et al., 2008]. 
In 1991, Catalona and colleagues reported the first study using serum PSA as a screening test 
for prostate cancer. Using a PSA cutoff of 4 ng/mL as the trigger for initiating prostate biopsy, 
they demonstrated that the combination of PSA with digital rectal examination (DRE) was 
superior to DRE alone for the detection of prostate cancer [Catalona et al., 1991]. Shortly after, 
in the late 1980s and early 1990s, use of PSA for the screening of prostate cancer became 
widespread in the United States, albeit without the benefit of a large, prospective trial to guide 
optimal screening strategies. 
After an elevated PSA dosage, the standard diagnostic technique for prostate cancer is the 
histopathological review of prostate tissue collected via needle biopsy. While this process is 
accurate for patients with extensive cancer, in many cases limited disease comprising small 
cancer foci, as the 80% of prostate cancer is, can be missed [Serenaite et al., 2015]. Prostate 
biopsy is associated with a false-negative rate of up to 30% due to sampling error and it is 
affected by the number of cores and pattern of sampling [Stewart et al., 2013]. Due to the 
substantial false-negative rate, needle biopsy of the prostate does not perform well at excluding 
a cancer diagnosis. Several nomograms containing different parameters have been proposed to 
aid the rebiopsy decision, but they are hampered by low accuracy [Chun et al., 2007; Benecchi 
et al., 2008]. Therefore, men with persistently elevated serum PSA values continue to undergo 
biopsy procedures, even though only 10-36% of second biopsies detect cancer; moreover, after 
each subsequent negative biopsy, cancer detection decreases [Trock et al., 2012]. Repeat 
biopsies in this group can affect patient care in two ways: it can delay cancer detection in 
patients with disease (and delay effective therapy) or subject cancer-free men to additional 
invasive biopsy procedures [Troyer et al., 2009].  
Although use of PSA as a biomarker in screening for prostate cancer has been well-
documented, its greatest limitation is that it is not specific for prostate cancer: serum PSA 
levels may rise not only during cancerogenesis, but also in benign processes such as benign 
prostatic hyperplasia, inflammation, infection, or trauma. Furthermore, the optimal upper limit 
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of the normal range for PSA is still unclear, and currently there is no consensus cutoff value for 
PSA that is specific for prostate cancer: PSA cutoff of 4 ng/ml has a calculated sensitivity of 
78.7% and a specificity of 59.2%. PSA concentration is also a poor discriminator of low- and 
high-risk disease, and clinically insignificant prostate cancer is common. Prostate cancer of 
clinical irrelevance represents the vast majority of all cases, as confirmed by autopsy studies 
that have identified indolent prostate cancers in up to 75% of men 85 years or older who 
ultimately died of causes other than prostate cancer [Tabayoyong & Abouassaly, 2015]. As a 
result, PSA screening has led to a concern for overdiagnosis and overtreatment of clinically 
indolent prostate cancers that ultimately pose no harm to the patient, therefore subjecting men 
to the morbidity of prostate cancer treatment, increased side effects and long term 
complications and a decreased quality of life: indeed, a great increase in needle core biopsies 
and radical prostatectomies has paralleled the increased use of PSA testing [Liljia et al, 2008].  
Lastly, this screening is associated to significant costs to the health care system, when the cost 
of the PSA test itself is considered in addition to the costs of diagnosis, staging, and treatment 
of screen-detected prostate cancers [Tawfik, 2015].  
The effects of PSA screening on mortality from prostate cancer are not yet clear: a recent meta-
analysis of five randomised controlled trials carried out in Europe and in US comparing the 
effect of PSA-screening vs. no screening on all-cause mortality and prostate cancer-specific 
mortality identified that screening does not significantly decrease prostate cancer-specific 
mortality and is associated with a high degree of overdiagnosis, treatment and screening-
related harms [Ilic et al, 2013]. Furthermore, guidelines recently updated by the European 
Association of Urology do not recommend widespread population-based screening by PSA 
[Heidenreich et al., 2014]. 
The debate over the use of PSA testing for early detection of prostate cancer still continues, 
and its inability to distinguish between indolent and aggressive prostate cancers makes hard to 
establish which tumours may kill the patient if left untreated: therefore, there is a urgent need 
to investigate into new biomarkers and tools for both prostate cancer diagnosis and prognosis. 
 
1.11 RATIONALE OF THE STUDY  
Large amount of literature indicate that epigenetic alterations are frequent in prostate cancer 
and are thought to contribute both to the disease onset and progression. Although the exact 
mechanisms of how these epigenetic alterations arise in prostate cancer are not understood, the 
fact that they occur at a much higher frequency than mutations and are common in 
premalignant stages of the disease make them attractive biomarkers for diagnosis, prognosis 
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and treatment response [Chiam et al., 2014]. Aberrant DNA methylation is the best-
characterized epigenetic alteration in prostate tumors: to date, almost 70 genes with promoter 
hypermethylation have been identified and reported as potential biomarkers of detection and 
progression. Notably, glutatione S-transferase pi 1 (GSTP1) gene is reported as 
hypermethylated in more of the 90% of prostate cancer and suggested as early detection 
biomarker [Valdes-Mora and Clark, 2015]. GSTP1 belongs to a family of enzymes that play an 
important role in detoxification by catalyzing the conjugation of many hydrophobic and 
electrophilic compounds with reduced glutathione. Aberrant GSTP1 methylation was detected 
in histologically negative biopsy samples, suggesting that epigenetic alterations in a first 
negative biopsy may be useful as potential markers of prostate cancer prediction on a repeat 
biopsy [Troyer et al., 2009; Trock et al., 2012; Stewart et al., 2013]. To improve the overall 
specificity and sensitivity, multiple studies have proposed that a panel of hypermethylated 
genes, including GSTP1, may be useful to discriminate prostate cancer from benign prostate 
hyperplasia [Bastian et al., 2005; Bastian et al., 2007; Ellinger et al., 2008; Baden et al., 2011; 
Yoon et al., 2012; Ashour et al., 2014]. Furthermore, promoter hypermethylation of GSTP1 
and other candidate genes, measured both in tissues and in body fluids, has been found to be 
repeatedly associated with clinicopathologic indicators of poor prognosis: biochemical 
recurrence (PSA relapse) [Bastian et al., 2007; Kristensen et al., 2014; Ashour et al., 2014], 
Gleason score [Bastian et al., 2005; Liu et al., 2008; Baden et al., 2011;  Yoon et al., 2012], 
and tumor stage [Bastian et al., 2005; Ellinger et al., 2008; Liu et al., 2008].   
Global DNA hypomethylation, generally defined as loss of methylation of highly repetitive 
DNA sequences such as LINE-1, has been studied to a much lesser extent than gene-specific 
hypermethylation. It may occur in early stages of prostate cancer and may be involved in the 
development of prostate intraepithelial neoplasia lesions [Cho et al., 2009; Yang et al., 2013], 
but it was described also at later stages of prostate cancer such as in metastatic prostate cancer 
and associated with prognostic parameters [Florl et al., 2004; Cho et al., 2007; 
Yegnasubramanian et al., 2008; Delgado-Cruzata et al., 2012]. Evidences on the role of global 
DNA hypomethylation in prostate cancer development and progression have been summarized 
in a recent meta-analysis [Zelic et al., 2015a], that underlined the potential value of this 
epigenetic mechanism as diagnostic and prognostic marker, but also suggested the necessity to 
overcome problems about heterogeneity and small sample size of the studies through well-
designed studies.  
Reported data suggest that in prostate cancer hypermethylation and hypomethylation are not 
mutually-exclusive, but rather concomitant events in close relationship [Florl et al., 2004; 
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Yegnasubramanian et al., 2008; Cho et al., 2009]. Prostate cancer has been proposed as a 
model of “epigenetic catastrophe”, particularly in relation to the widespread changes observed 
in DNA methylation patterns (Figure 1.1). An overall decrease in 5mC occurs since first 
stages; in addition, at specific gene loci, promoter hypermethylation is one of the earliest 
molecular aberrations and persists throughout disease progression. Global hypomethylation 
becomes more extensive as disease becomes metastatic [Perry et al., 2010].  
 
Figure 1.1. Changes in methylation patterns during prostate cancer development, according to 
the model of the epigenetic catastrophe.  
 
 
 
 
 
 
 
 
 
 
 
Methylation status of selected genes has been explored also in non-neoplastic tissue adjacent to 
tumor, to assess if aberrant methylation already occurs in tissues without features of 
malignancy, to evaluate if it is comparable to the epigenetic events of primary tumor, 
according to the hypothesis of the “epigenetic field effect” in prostate cancer, and also if it is 
able to predict the risk of recurrence of malignant disease [Chai and Brown, 2009].  
The concept of field effect (or field cancerization) was based on observations that cancer 
developed in multifocal areas and that abnormal tissue surrounded the tumor, suggesting that 
neoplastic or preneoplastic cells existed in a histologically normal field proximal to cancer 
tissue [Mehrotra et al., 2008]. Hanson and colleagues have reported hypermethylation of the 
promoter of two genes (GSTP1 and RARβ2) both in normal epithelium and stroma isolated 
from regions adjacent to the tumors [Hanson et al. 2006] and, more recently, promoter 
methylation of selected gene was found increased in non-neoplastic tissue adjacent to tumor 
[Mehrotra et al., 2008; Steiner et al., 2010; Jentzmic et al., 2012]. By contrast, to our 
knowledge, global DNA hypomethylation in non neoplastic tissue adjacent to prostate tumor 
has not been investigated yet.  
From Perry et al., Nat Rev Urol (2010) 
 25
DNA methylation, as discussed above, is mediated by enzymes belonging to the family of the 
DNA methyltransferases (DNMTs). Documented association between DNMT3b 
overexpression and increased methylation [Nosho et al., 2009], as well as between DNMT3b 
inhibition and global and gene-specific DNA hypomethylation [Biswal et al., 2012], indicate a 
direct relation between DNMT3b activity and DNA methylation status in the tumor. DNMT3b 
overexpression has been described in several types of cancers [Lin and Wang, 2014], including 
prostate [Kobayashi et al., 2011], and associated to disease progression [Hayette et al., 2012; 
Chen et al., 2014], although in prostate cancer this relationship has been observed only in in 
vitro assays [Gravina et al., 2013].  
Single nucleotide polymorphisms (SNPs) in the DNMT3b gene have been reported to increase 
the transcriptional activity of the promoter of DNMT3b, thus producing an effect similar to 
enzyme overexpression. This effect lastly may play a role in aetiology and progression in a 
wide range of malignant solid tumors and hematologic neoplasms, prostate cancer included 
[Singal et al., 2005], as recently reviewed [Duan et al., 2015].  
Regarding a possible effect of DNMT3b polymorphisms on global DNA hypomethylation in 
cancer cells, to our knowledge this has not been evaluated yet. 
 
 26
2. AIMS OF THE STUDIES 
 
This research project includes three studies, conducted on three types of prostate tissue: non-
neoplastic prostate tissue (STUDY 1), prostate tumor tissue (STUDY 2 and 3) and non-
neoplastic tissue adjacent to tumor (STUDY 2). In general in these studies we explored the role 
of methylation status in the development and progression of prostate cancer, and the possible 
regulation of mechanisms leading to a given methylation status through the efficiency of 
DNMT3b enzyme. The relevance of the methylation pattern could suggest a possible role of 
global hypomethylation and gene-specific hypermethylation of selected genes as a diagnostic 
and a prognostic marker.  
 
⇒ STUDY1 
A case-control study conducted on an unselected series of men who received at least two 
prostate biopsies at the San Giovanni Battista Hospital, Turin, between 1993 and 2003 to 
evaluate if aberrant methylation detected on the first biopsy may serve as prediction marker of 
prostate cancer diagnosis in a subsequent biopsy; 
 
⇒ STUDY2   
A cohort study that involved consecutive prostate cancer patients diagnosed at the San 
Giovanni Battista Hospital between 1982 and 1996 aiming to understand if global DNA 
hypomethylation evaluated both in tumor and in non-neoplastic tissue adjacent to tumor may 
have prognostic value for prostate cancer; 
 
⇒ STUDY 3   
A cohort study performed on consecutive prostate cancer patients diagnosed at the San 
Giovanni Battista Hospital between 1982 and 1996, a part of them already involved in the 
STUDY 2, to evaluate if selected polymorphisms of DNMT3b gene could have an effect on 
aberrant methylation and may be implicated in prostate cancer prognosis.  
 
 
 27
3. STUDY 1  
“LINE-1 HYPOMETHYLATION AND GSTP1 HYPERMETHYLATION ON INITIAL 
NEGATIVE PROSTATE BIOPSY AS MARKERS OF PROSTATE CANCER ON A 
REBIOPSY” 
Overall aim of the study was to assess if aberrant methylation markers measured in a first 
negative prostate biopsy may be associated with prostate cancer diagnosis in a subsequent 
biopsy. Specifically, we evaluated if global hypomethylation, measured through LINE-1 
methylation, and GSTP1 hypermethylation detected  in an initial negative biopsy are markers 
of the probability to detect prostate cancer in a rebiopsy.  
 
The study was approved by the Local Ethical Committee. 
Results of this study have been recently published [Zelic et al., 2015b]. 
 
3.1 STUDY DESIGN AND PARTICIPANTS SELECTION 
We conducted a case-control study within an unselected cohort of men who underwent prostate 
biopsy, TURP or partial prostatectomy between 1993 and 2003 at the San Giovanni Battista 
Hospital, Turin, Italy, and whose archived formalin fixed paraffin embedded (FFPE) tissue 
samples were available at the two Pathology Wards of the Hospital. The two Pathology Wards, 
hereafter referred to as Ward 1 and Ward 2, were associated with different Urology Wards of 
the Hospital and were included in the study for replication purposes. 
In total, in the two Wards, 8755 men underwent at least one procedure (i.e. biopsy, TURP or 
partial prostatectomy) during the study period, of whom 1105 underwent two or more 
consecutive procedures. We restricted the study to 737 subjects with a minimum of three 
months between the two procedures. For subjects with tissue samples available from more than 
three consecutive procedures, only the last three were considered. 
Case subjects were patients with a histological confirmation of prostate cancer in the last 
biopsy, which was used as the index sample. Subjects with only one negative prostate tissue 
sample available prior to the positive index sample were counted as one case, while subjects 
with two available samples were counted as two cases, leading to 145 potential cases in Ward 1 
and 99 potential cases in Ward 2. Original diagnostic slides from all the potential cases were 
traced and re-evaluated to assign a harmonized Gleason score. When Gleason score could not 
be re-evaluated the original Gleason score available from the pathology report was used or it 
was considered as missing. Cases without a matched control of for whom prostate cancer 
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diagnosis could not be confirmed were excluded, leaving 115 cases in Ward 1 and 84 cases in 
Ward 2 for further analysis. 
Non-case subjects were patients who remained prostate cancer-free at the last prostate 
sampling. Non-case subjects with two negative prostate tissue samples available were counted 
as one potential control, while non-case subjects with three negative samples available were 
counted as two or three potential, thusleading to 293 potential controls in Ward 1 and 365 
potential controls in Ward 2.  
Within each Ward, actual controls were matched to cases (1:1 ratio) on calendar year of 
sampling (four-year groups), age (five-year groups) and time between the first and second 
sampling (six-months groups). Controls with high-grade prostatic intraepithelial neoplasia 
(HGPIN) or atypical small acinar proliferation (ASAP) on the index procedure were excluded: 
HGPIN is an abnormality of the prostatic gland considered to precede the development of 
prostate cancer, while ASAP generally is not considered a pre-malignancy, but it is an 
expression of diagnostic uncertainty. After the sampling procedure, 94 controls in Ward 1 and 
84 controls in Ward 2 remained for analysis. 6 cases (4 in Ward 1 and 2 in Ward 2) and 2 
controls (2 in Ward 1) were excluded from the study because their FFPE blocks did not contain 
sufficient amount of prostate tissue needed for the molecular analyses. Finally, we randomly 
excluded one case (14 in Ward 1 and 7 in Ward 2) and one control (6 in Ward 1 and 3 in Ward 
2) whenever two cases/controls originated from the same case/control subject and, at the same 
time, we minimized loss of information by trying to preserve at least one case and one control 
in each matching stratum. Process of selection and exclusion of cases and controls is 
summarized in Figure 3.1. 
For both cases and controls, the molecular analyses focused exclusively on the first negative 
sample, meaning that the index procedure used to define cases and controls (i.e. subsequent 
positive or negative biopsy) was not analyzed. This approach is consistent with the aim of the 
study, i.e. assessing molecular markers used to help the rebiopsy decision.  
 
3.2 METHODS 
3.2.1 Choice of FFPE blocks  
Analyses were performed on one tissue sample for each case and control. If a case or a control 
had more than two FFPE blocks we randomly selected one block. If a case or a control had 
more than two tissue samples in the selected FFPE block we selected the largest tissue samples 
and cut three to five (10 µm thick) sequential sections avoiding areas of chronic inflammation, 
fibromuscular stroma, glandular atrophy and epithelial dysplasia. 
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3.2.2 DNA extraction 
Tissue slices cut from FFPE blocks were first dewaxed three times in xylene and washed three 
times in 100% ethanol, then genomic DNA was extracted and purified using the commercially 
available QIAamp ® DNA FFPE Tissue Kit (Qiagen, Hilden, Germany): after removing the 
residual ethanol, the tissue was dried at room temperature (or in thermal block at set 37°C to 
shorten the time) and was incubated with 180 µl of buffer ATL (tissue lysis buffer) and 20 µl 
of proteinase K for 1h at 56°C, and then for 1h at 90°C. To lyse prostate cells 200 µl of Buffer 
AL was added to the sample, and the obtained lysate was washed with 200 µl of absolute 
ethanol, and then transferred into a spin column containing a silica membrane of resin. The 
resin holds the DNA molecules by tying. The silica membrane was washed twice with washing 
buffers AW1 and AW2, then genomic DNA was eluted with a variable volume of elution 
buffer (ATE): 42 µl of ATE for DNA extracted from biopsies, 72 µl for DNA extracted from 
TURPs and prostatectomies. The extracted DNA was then stored at -80°C. The concentration 
of each DNA sample was assessed by UV-visible spectrophotometer (NanoDrop Technology). 
 
3.2.3 Sodium bisulfite modification 
Genomic DNA samples, along with fully methylated [CpGenomeTM universal methylated 
DNA (Chemicon Co.)] and fully unmethylated controls [EpiTect Control DNA, unmethylated 
(Qiagen, Hilden, Germany)], underwent sodium bisulfite conversion using the commercially 
available kit EpiTect bisulfite kit (Qiagen, Hilden, Germany). 1000 ng of DNA were modified, 
when possible, in a maximum volume of 40 µl, as recommended by the manufacturer’s 
protocol. Genomic DNA was added to 85 µl of sodium bisulfite Mix, 15 µl or 35 µl of DNA 
Protect Buffer, and the final total volume of 140 µl was reached with distilled H2O. Samples 
were placed in a thermal cycler for the 5 hours-long conversion reaction, with thermal profile 
as follows: 5’ at 95°C, 25’ at 60°C, 5’ at 95°C, 85’ at 60°C, 5’ at 95°C, 175’ at 60°C and final 
hold at 20°C. 
Samples were then added to 310 µl of Buffer BL +10 µg of carrier RNA and washed 250 µl of 
absolute ethanol, after that were passed into a spin column and the washed with 500 µl of BW 
(wash buffer). Desulfonation was performed by adding 500 µl of BD (Desulfonation Buffer) to 
the column and incubating for 15’ at room temperature. The spin column was washed twice 
with 500 µl of BW and allowed to dry. Elution was performed in two steps, using 21 µl of EB 
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(elution buffer) in each step, then resulting in a total volume of 42 µl of bisulfite-converted 
DNA that was stored at -80°C. 
 
3.2.4 Quantification of CpG methylation by Pyrosequencing 
Analysis of LINE-1 (GenBank accession number X58075) and GSTP1 (GenBank accession 
number M24485) promoter methylation status were performed using PyroMark Q24 MDx 
(Qiagen, Hilden, Germany). Primers, which amplify a 98bp-long fragment of LINE-1 promoter 
containing three CpG sites (positions 819, 826 and 829), and a 72bp-long fragment of GSTP1 
promoter containing four CpG sites (positions 1038, 1040, 1043, 1049), were designed outside 
the CpG sites. PCR and sequencing primers are listed in Table 3.1. We performed PCR 
reaction in a total volume of 30 µl containing 1X buffer (KCl), 2 mM MgCl2, 0.8 mM dNTPs, 
0.5 µM of each primer, 0.05 U Taq polymerase and 6 µl of bisulfite-converted DNA with the 
following cycling profile: 95°C for 10 min followed by 45 cycles of denaturation at 95°C for 
30 sec, annealing at 55°C for 1 min for LINE-1 and at 50°C for 1 min for GSTP1, extension at 
72°C for 1 min and final extension at 72°C for 10 min. The PCR product (20 µl) was added to 
18 µl of distilled water and incubated under shaking with 40 µl of binding buffer and 2 µl of 
streptavidin-coated beads. Pyrosequencing reaction was performed in a total volume of 25 µl, 
including 24.85 µl of 20 mM Tris-Acetate, 5 mM MgAc2 and 0.15 µl of 50 µM sequencing 
primer (final concentration 0.3 µM) in a PyroMark Q24 MD instrument. Pyrosequencing 
methylation assays were created according to the manufacturer’s instruction. Methylation 
quantification was achieved using the provided software, and expressed for each DNA locus as 
percentage of methylated cytosines divided by the sum of methylated and unmethylated 
cytosines. Positive controls for methylated [CpGenomeTM universal methylated DNA 
(Chemicon Co.)] and unmethylated status [EpiTect Control DNA, unmethylated (Qiagen, 
Hilden, Germany)] were included in each pyrosequencing run. Analyses on LINE-1 
methylation were conducted ensuring that the matched case and control samples were analyzed 
within the same batch; thus, if analyses for a case or control had to be re-run, we re-analyzed 
the whole corresponding stratum, including both the case and the matched control(s).  
 
3.2.5 Statistical analyses  
Analyses were first conducted in Ward 1 and then replicated in Ward 2. Thus, all analyses 
were conducted in the two Wards separately, with the exception of the subgroup analyses in 
which the two Wards were combined to increase statistical power.  
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Since LINE-1 and GSTP1 methylation analyses involved more than 1 CpG site, mean 
methylation levels across the CpG sites were used. In sensitivity analyses using the maximum 
methylation level, results were only marginally changed. We thus have reported only estimates 
based on the mean methylation. In order to facilitate interpretation of the results LINE-1 
methylation was categorized into four categories (<70%, 70-74%, 75-79%, ≥80%) and 
analyzed using 70-74% as the reference. To investigate possible non-linearities, we 
additionally modeled LINE-1 methylation in both Wards using cubic splines with four internal 
knots based on the tertiles of the LINE-1 distribution, and reported the results graphically using 
a methylation value of 72.7% as the reference. GSTP1 methylation was dichotomized using an 
a priori selected cut-off of 5% (based on a detection limit of pyrosequencing technique), where 
subjects with GSTP1 methylation ≥5% were considered as hypermethylated and subjects with 
GSTP1 methylation <5% as unmethylated.  
We used conditional logistic regression to estimate odds ratios (ORs), and corresponding 95% 
confidence intervals (95% CIs), of the risk of prostate cancer diagnosis on a rebiopsy for 
LINE-1 hypomethylation and GSTP1 hypermethylation. Strata were defined by the matching 
variables, and we further adjusted for time between the first and second sampling (continuous 
variable), number of cores sampled at the first biopsy (≤2, 3-5, ≥6 cores categories), number of 
samples prior to the index sample (1, 2 and ≥3) and, mutually, for GSTP1 and LINE-1 
methylation. The two Wards were combined to estimate the amount of diagnostic information 
added independently by GSTP1 (<5%, ≥5) and LINE-1 methylation (modelled by restricted 
cubic splines), by comparing the models including these two markers with the model without 
them, and calculating the Akaike Information Criterion (AIC) for each of the models. After 
combining the two Wards, we also conducted subgroup analyses by stratifying on time 
between the first and the second sampling, <12 vs. ≥12 months, and Gleason score, ≤3+4 vs. 
≥4+3. We chose not to treat Gleason score 7 as a homogenous group as this has been reported 
to lead to a loss of prognostic information [Stark et al., 2009; Amin et al., 2011]. However, we 
performed sensitivity analyses using Gleason score 8 as the threshold. In addition, we 
calculated the observed sensitivity in cases and specificity in controls for GSTP1 ≥5% and 
LINE-1 <70%. All statistical analyses were conducted using STATA 12 (STATA Corporation, 
College Station, TX, USA). 
 
3.3 RESULTS 
In total, 97 cases and 86 controls in Ward 1 and 75 cases and 81 control in Ward 2 remained 
for the molecular analyses (Figure 3.1). Preliminary analyses of LINE-1 methylation revealed 
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higher methylation levels in TURPs than in biopsy samples (Figure 3.2), suggesting that LINE-
1 methylation levels are higher in the tissue sampled from the transition zone. We therefore 
restricted the study to biopsies only, and excluded cases and controls sampled by TURP and 
prostatectomy and subjects who were left without cases or controls within the matching strata. 
Overall, 67 cases and 62 controls in Ward 1 and 62 cases and 66 controls in Ward 2 remained 
for the final analyses (Figure 3.1). 
Table 3.2 summarizes some selected characteristics of cases and controls divided by Ward. 
Mean LINE-1 methylation was lower in cases than controls in Ward 1 but not in Ward 2, while 
GSTP1 methylation was higher in cases than controls in both Wards. The two Wards included 
slightly different patients. Cases in Ward 1 had a higher proportion of high grade tumors 
(≥4+3) than those in Ward 2. Additionally, controls in Ward 1 had higher LINE-1 methylation 
and lower GSTP-1 methylation than controls in Ward 2. In both Wards, biopsies with at least 6 
cores were sampled more frequently from controls than from cases.  
Table 3.3 reports results for LINE-1 methylation, categorized into four categories. The adjusted 
OR of prostate cancer diagnosis on the rebiopsy for LINE-1 hypomethylation (<70% vs. 70-
74%) was 2.1 (95% CI: 0.5-9.1) in Ward 1 and 1.6 (95% CI: 0.4-6.1) in Ward 2. When LINE-1 
was modelled using spline regression (Figure 3.3) we found an increased risk of prostate 
cancer at low methylation levels in both Wards, but, while in Ward 1 the relationship flattened 
with increasing LINE-1 methylation, in Ward 2 there was a U-shaped relationship with an 
increased risk of prostate cancer diagnosis also at high levels of LINE-1 methylation. GSTP1 
hypermethylation was associated with diagnosis of prostate cancer at the second biopsy in both 
Wards (Ward 1: OR=5.1, 95% CI: 1.7-15.0; Ward 2: OR=2.0, 95% CI: 0.8-5.3) (Table 3.3). As 
reported in Table 3.4, when we stratified by the time between the first and the second biopsy, 
neither for LINE-1 hypomethylation nor for GSTP1 hypermethylation there was clear evidence 
of heterogeneity with the time between the first and second biopsy. In the analysis stratified by 
Gleason score, associations were stronger for Gleason score ≥4+3 for both GSTP1 methylation 
(OR2=9.2, 95% CI: 2.0-43.1) and LINE1 methylation <70% (OR2=9.2, 95% CI: 1.4-59.3). 
When we used Gleason score 8 as the cut-off, the associations with prostate cancer diagnosis 
remained stronger for more aggressive tumors (data not shown).  
When the two Wards were combined, GSTP1 (p=0.0068) independently improved the 
predictive capability of the model (Table 3.5) and the model associated with the lowest AIC 
included only GSTP1 methylation. However, when the analysis was restricted to cases with 
Gleason score ≥4+3 and corresponding controls, the model with the lowest AIC included both 
LINE-1 and GSTP1 methylation (Table 3.5). For both GSTP1 and LINE-1, the specificity was 
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higher than the sensitivity (86.7% and 25.2% for GSTP1; 88.3% and 15.5% for LINE-1). 
When analyses were restricted to cases with Gleason score ≥4+3, the sensitivity and the 
specificity were 85.5% and 26.5% for GSTP1 and 88.2% and 23.57% for LINE-1. 
 
3.4 DISCUSSION 
It has been proposed that global DNA hypomethylation and gene-specific hypermethylation 
coexist in prostate cancer tissue and therefore can be used as markers of prostate cancer 
diagnosis and prognosis [Ehrlich et al., 2009 Cho et al., 2007; Yegnasubramanian  et al., 2008]. 
In this study we assessed the relationship between LINE-1 hypomethylation and GSTP1 
hypermethylation in men with a histologically negative initial biopsy and prostate cancer 
detection in a subsequent tissue sample. While GSTP1 methylation alterations seem to be 
associated with prostate cancer diagnosis, and the results were replicated in two independent 
Wards, effects were weaker and less consistent for LINE-1, with a possible exception of 
extremely low LINE-1 methylation levels. 
Previously, a number of studies with a study design similar to ours have evaluated the 
hypermethylation of GSTP1 promoter in the first negative prostate biopsies [Troyer et al., 
2009; Trock et al., 2011; Stewart et al., 2013]; however, to our knowledge, any research group 
have analyzed global DNA hypomethylation in repeat prostate biopsies before. Three previous 
studies have evaluated the methylation status of some selected genes, that have been tested on 
a negative biopsy as a predictor of prostate cancer detection on a rebiopsy: GSTP1, APC and 
RAR-2β [Troyer et al., 2009], GSTP1 and APC [Trock et al., 2011],  or GSTP1, APC and 
RASSF1 [Stewart et al., 2013]. In addition, the high negative predicted value obtained 
combining GSTP1, APC and RASSF1 [Stewart et al., 2013] have been validated in the recent 
DOCUMENT multicenter study [Partin et al., 2014].  
The three studies used different approaches to calculate sensitivity and specificity; however, in 
all three studies, GSTP1 was found to have a rather high specificity (75-85%) and rather low 
sensitivity (36-52%), and in two studies APC had higher sensitivity (46-95%) but lower 
specificity (40-78%). While our results on GSTP1 methylation are consistent with previous 
studies, the results for LINE-1 methylation do not suggest that this is a strong candidate marker 
for prostate cancer diagnosis, although they offer a novel insight into the possible association 
of the extremely low levels of LINE-1 methylation (i.e. <70% category, or ≤67% as visible 
from spline regression in Figure 3.3) with the risk of prostate cancer diagnosis on a rebiopsy. 
However, these results were less conclusive due to small number of subjects in these 
categories, as 15.5% of cases had LINE-1 methylation <70% and only 6.2% of cases had 
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LINE-1 methylation ≤67%. For both GSTP1 hypermethylation and LINE-1 hypomethylation 
the relationship with prostate cancer was stronger in the more aggressive tumors (i.e. those 
with Gleason score ≥4+3). For GSTP1, these results are in line with the findings of a previous 
study [Stewart et al., 2013], where more aggressive tumors (Gleason score ≥7) were found to 
have higher methylation and more epigenetic abnormalities in the initial negative biopsy. In 
addition, when the two Wards were combined and the analysis was restricted to cases with 
Gleason score ≥4+3 and corresponding controls, the model with the best prediction of the 
probability of prostate cancer diagnosis included both GSTP1 and LINE-1 methylation, 
suggesting that global DNA hypomethylation, specifically extreme global hypomethylation, 
could be considered, in addition to gene-specific hypermethylation, in nomograms for the 
decision on whether to rebiopsy or not. 
Our results revealed that LINE-1 methylation level is higher in TURPs compared to biopsies, 
therefore suggesting that, from the molecular point of view, tissue sampled from the 
transitional zone is different from that of the peripheral zone. This is in line with the results of 
previous studies, which found that peripheral and transitional tissue retrieved from normal 
prostate show differential gene expression profiles, therefore highlighting the profound 
molecular differences between these two zones [van der Heul-Nieuwenhuijsen et al., 2006; 
Noel et al., 2008].   
Our study has strengths: the underlying population from which cases and controls originate 
was an unselected series of men who underwent repeat biopsies at the San Giovanni Battista 
hospital, Turin, Italy, with a 19% risk of being diagnosed with prostate cancer on a rebiopsy, 
which is in line with previous studies [Stewart et al., 2013]. For quantitative analysis of LINE-
1 and GSTP1 methylation we used pyrosequencing which, in contrast to quantitative 
methylation specific PCR (qMS-PCR) used for GSTP1 analysis in prior studies [Troyer et al., 
2009; Trock et al., 2011; Stewart et al., 2013], detects low levels of methylation as methylation 
in each CpG site is measured independently [Havik et al., 2012]. Pyrosequencing has also been 
reported to have a higher sensitivity and accuracy than qMS-PCR [Quillien et al., 2012]. A 
high sensitivity is particularly important for analyses of GSTP1, as GSTP1 methylation is 
typically low in non-tumor prostate tissue, while high accuracy is particularly relevant for 
LINE-1, as LINE-1 methylation is an indicator of global methylation and is associated with a 
rather low variance. Furthermore, we paid attention to the possible batch effect in LINE-1 
methylation quantification by pyrosequencing by analyzing matched cases and controls within 
the same batch: we could not completely eliminate the possibility of misclassification due to 
the molecular analyses, but we ensured that the misclassification was non-differential.  
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The main limitation of this study is that we lacked information on the various clinical and 
pathological parameters that are typically used to predict prostate cancer on a subsequent 
biopsy, including PSA and PSA derivatives, prostate volume, digital rectal examination finding 
and family history of prostate cancer. This hampers the estimation of the actual discrimination 
potentials of GSTP1 and LINE-1 methylation when added to the current nomograms. It is 
important to note, however, that our study was nested in a cohort of men who underwent a 
rebiopsy, which implies that the clinical parameters typically used to guide a rebiopsy decision 
were implicitly taken into account. Our markers therefore, to some extent, work in addition to 
these clinical variables. It should also be acknowledged that these two markers might not be 
enough to discriminate the disease on their own, but they could be used in addition to other 
previously suggested markers such as PSA levels, methylation in APC, RAR-2β, RASSF1, 
early prostate cancer antigen or gene hypermethylation in the urine samples collected at the 
time of the rebiopsy.  
In our study, the quality of the DNA extracted from the FFPE blocks could potentially be 
suboptimal, as the samples included in this study were 10 to 22 years old; however, it has been 
shown that DNA, especially short target sequences of DNA suitable for methylation status 
analysis, can be efficiently extracted from FFPE blocks archived for more than 20 years 
[Gillio-Tos et al., 2007]. Finally, due to the small number of subjects at the extremes of the 
LINE-1 distribution (i.e. LINE-1 methylation <70% and >80%) and the observed non-linear 
relationship, our study did not have enough power to give precise estimates of the association 
between the extremes of LINE-1 methylation and the risk of prostate cancer diagnosis on a 
subsequent biopsy. 
In conclusion, in two parallel analyses conducted among patients seen in two Wards of a large 
Hospital in Italy, we found that promoter methylation of GSTP1 measured in a negative biopsy 
tissue is associated with prostate cancer diagnosis on a rebiopsy, especially for more aggressive 
tumors. These results were consistent in the two Wards and they support prior findings that 
GSTP1 methylation is a specific predictor of malignancy on a prostate rebiopsy. Validation 
across Wards for LINE-1 was achieved only for low methylation levels and prior evidence is 
sparse. Its predictive ability, especially for more aggressive tumors, should thus be replicated 
in future studies including a larger number of patients with extremely low LINE-1 methylation 
values. 
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3.5 TABLES AND FIGURES 
 
 
Figure 3.1. Flow chart of the case and control selection. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Zelic et al., Clin Cancer Res 2015)  
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Figure 3.2. Kernel density estimate of LINE-1 methylation distribution in biopsies vs. TURP 
in the Ward 1 and Ward 2 combined. Cases and controls are presented separately. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Zelic et al., Clin Cancer Res 2015)  
 
 
Figure 3.3. Association between LINE-1 methylation on a negative biopsy and risk of prostate 
cancer diagnosis on a rebiopsy in the two Wards separately.  
 
 
 
 
 
 
 
 
 
 
 
 
Estimates are, adjusted for matching variables and time between the two samples, number of cores sampled at the 
biopsy, number of biopsies prior to the index biopsy and GSTP1 methylation (the upper 95% limit is restricted to 
<200 and the lower 95% limit is restricted to >0.03). 
 
(Zelic et al., Clin Cancer Res 2015)  
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Table 3.1. PCR and sequencing primers for amplification of a fragment of LINE-1 and GSTP1 
promoter. 
 
Primer LINE-1 promoter GSTP1 promoter 
Forward 5’-TTTGAGTTAGGTGTGGGATATAGTT-3’ 5’-GATTTGGGAAAGAGGGAAAGGT-3’, 
Reverse 5'-Biot-CACCTAAAAAATCCAATCACTCC-3' 5’-Biot-CAAAAAAACGCCCTAAAATCC- 3’ 
Sequencing 5’-TTAGGTGTGGGATATAGTTT-3’ 5’-GGTTTTTTYGGTTAGTTG-3’ 
 
 
Table 3.2. Selected characteristics of cases and controls by Ward. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (Zelic et al., Clin Cancer Res 2015)  
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Table 3.3. LINE-1 methylation and GSTP1 hypermethylation on a negative biopsy and risk of 
prostate cancer diagnosis on a rebiopsy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OR1, odds ratio inherently adjusted for matching variables; OR2, odds ratio adjusted as OR1 and for time between the two 
biopsies, number of cores sampled at the biopsy, number of biopsies prior to the index biopsy and GSTP1/LINE-1 
methylation; CI, confidence intervals. 
aCases without information on GSTP1 methylation and number of cores, and corresponding controls within the matching 
strata, were excluded from the analyses. 
 
(Zelic et al., Clin Cancer Res 2015)  
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Table 3.4. LINE-1 methylation and GSTP1 hypermethylation on a negative biopsy and risk of 
prostate cancer diagnosis on rebiopsy stratified by time between the two samplings and 
Gleason score (two Wards combined). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OR1, odds ratio inherently adjusted for matching variables; OR2, odds ratio adjusted for matching variables and for time 
between the two biopsies, number of cores sampled at the biopsy, number of biopsies prior to the index biopsy and 
GSTP1/LINE-1 methylation; CI, confidence intervals. 
aCases without information on GSTP1 methylation and number of cores, and corresponding controls within the matching 
strata, were excluded from the analyses. 
bAnalysis based on subset of cases with specified Gleason score and all the controls within the matched stratum. 
 
(Zelic et al., Clin Cancer Res 2015)  
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Table 3.5. Assessment of the predictive ability of models including GSTP1 methylation, 
LINE-1 methylation, or both markers, in comparison with the core model with no methylation 
markers. 
 
 
 
 
 
 
   
 
 
 
 
 
AIC, Akaike Information Criterion. 
aCore model includes time between the two biopsies, number of cores sampled at the biopsy and number of 
biopsies prior to the index biopsy. 
bp-values for the comparison with the core model. 
 
(Zelic et al., Clin Cancer Res 2015)  
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 4. STUDY 2 
“GLOBAL DNA HYPOMETHYLATION IN TUMOR TISSUE AND IN NON-
NEOPLASTIC TISSUE ADJACENT TO TUMOUR AS A POSSIBLE PROGNOSTIC 
BIOMARKER FOR PROSTATE CANCER” 
 
This study aimed at evaluating the potential of global DNA hypomethylation, measured in 
prostate tumor tissue as well as in non-neoplastic tissue adjacent to tumor, as a predictor of 
prostate cancer-specific mortality.  
 
Specifically, we wanted to: 
1. Estimate the association between decreased global DNA methylation level in tumor 
tissue and prostate cancer-specific mortality to explore its value as a possible 
prognostic marker; 
2. Study the global DNA methylation level in non-neoplastic tissue adjacent to tumour to 
understand if this epigenetic alteration could be an early marker of prostate cancer 
development, and evaluate if it is correlated with risk of death from prostate cancer; 
3. Evaluate if global DNA hypomethylation in tumor and in non-neoplastic tissue adjacent 
to tumor is associated with Gleason score.  
 
We estimated the loss of global DNA methylation in terms of methylation levels of the 
promoter of the retrotransposon LINE-1, a widely used approach since LINE-1 elements are 
abundant, globally distributed along the genome and heavily methylated. Evaluation of LINE-1 
methylation level can serve as a reliable surrogate marker for global genomic methylation 
[Lisanti et al., 2013].  
 
The study was approved by the Local Ethical Committee. 
 
4.1 PRELIMINARY DATA 
This cohort study represent a further step of our ongoing project on the role of epigenetic 
alterations as possible prognostic biomarkers for prostate cancer. In our first study [Richiardi et 
al., 2009] we studied the methylation status of the promoter of three selected genes to 
understand their potential value as markers of prostate cancer progression. Genes have been 
selected on the basis of the previously reported association between their aberrant methylation 
status and clinical features of poor prognosis in prostate cancer patients. The study involved 
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two indipendent cohorts of, in total, 459 consecutive prostate cancer patients diagnosed 
between 1982 and 1988 (1980s cohort) or between 1993 and 1996 (1990s cohort), at the 
pathology ward of the San Giovanni Battista Hospital, Turin, Italy.  
Patients were followed up from the date of the pathology report to February 2006 for the 1980s 
cohort, and to January 2007 for the 1990s cohort. Information on vital status at the end of the 
follow up and copies of the death certificates came from the demographic offices: information 
from death certificates were used to classify the cause of death as either prostate cancer, or 
other causes. Dead patients were censored on their date of death. For each patient we had 
available some clinical information (age, source of tumor tissue, place of residence and tumor 
grade) retrieved from pathology reports. We did not have information on PSA levels or other 
clinical characteristics. For each patient archival formalin-fixed paraffin-embedded tumor 
tissue, withdrawn through biopsy, TURP or prostatectomy procedure, was available; diagnostic 
slides were re-evaluated by a single pathologist in order to assign a uniform Gleason score 
according to current guidelines.  
We studied the prostate cancer survival in association with promoter hypermethylation in 
GSTP1, APC, and RUNX3: we found that hypermethylation of APC promoter is associated 
with prostate cancer mortality, particularly among those with a highly to moderately 
differentiated tumor (Gleason score <8). A similar association was found for hypermethylation 
in RUNX3 in patients diagnosed during the 1990s and, in the two cohorts combined, the risk of 
death from prostate cancer increased with increasing number of methylated genes.  
The second study [Richiardi et al., 2013] was nested in the first and involved 157 prostate 
cancer patients of the previous cohort who had available, in their FFPE tissue blocks, well-
recognizable areas of non-neoplastic tissue adjacent to tumor (NTAT), identified and 
highlighted by the uropathologist by re-analyzing the diagnostic slides. In this study, the follow 
up of the patients has been extended until August 2010. Apart from patients for who we could 
not retrieve non-neoplastic tissue adjacent to tumor in any diagnostic slide, we also excluded a-
priori patients diagnosed during the 1980s who underwent biopsy procedure. The assumption 
was that, since during the pre-PSA era prostate cancer diagnosed were bigger and more 
advanced that those diagnosed during the 1990s, their diagnostic slides included mainly 
neoplastic tissue and were associated with considerable technical problems in isolating NTAT 
without contamination from tumoral tissue.  
We evaluated  the methylation status of GSTP1 and APC promoter in NTAT to assess first if 
aberrant methylation is already detectable in the apparently healthy tissue near to the tumor, 
according to the hypothesis of the “field cancerization”, and also whether these molecular 
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changes are potential candidates as prognostic markers by testing their association with 
mortality from prostate cancer. We found that hypermethylation of APC and GSTP1 occurred 
in the 40-45% of NTAT, supporting the hypothesis that DNA hypermethylation is an early 
event in carcinogenesis that can be detected before the tumour becomes morphologically 
evident. Hypermethylation of APC and GSTP1 correlated with methylation pattern in prostate 
tumour tissue, in line with the notion of field cancerisation in prostate cancer. More 
importantly, gene-specific hypermethylation was strongly associated with mortality from 
prostate cancer, further supporting the hypothesis on the role of aberrant hypermethylation in 
prostate cancer progression.  
 
4.2 STUDY POPULATION AND AVAILABLE DATA 
This cohort study was carried out on the 157 prostate cancer patients who have been previously 
selected in the second nested study [Richiardi et al., 2013]. Specifically, the study involved 
patients with prostate cancer diagnosed between 1982 and 1988 who underwent TURP or 
radical prostatectomy procedures, and patients diagnosed between 1992 and 1996 who 
underwent biopsy, TURP or radical prostatectomy procedures, conducted at the Pathology 
Ward of the San Giovanni Battista Hospital, Turin, Italy.  
All the clinical data available for the 157 prostate cancer patients involved in the study are 
summarized below:  
 
? Clinical information (age, source of tissue, place of residence and tumor grade) from 
pathology reports; 
? Gleason score re-evaluated by a single uropathologist according to current guidelines; 
? Life status at the end of the follow up (until August 2010); 
? Cause of death from death certificates. 
 
In addition, molecular data on methylation status of the promoter of some selected genes have 
been provided by the previous studies: 
 
? APC, GSTP1 and RUNX3 promoter methylation in tumor tissue; 
? APC and GSTP1 promoter methylation in non-neoplastic tissue adjacent to tumor. 
 
Since that, for a part of the subjects, DNA extracted from their NTAT tissue has been 
terminated during the previous study, we overcome the limitation of incomplete values of 
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LINE-1 methylation level in NTAT using the multiple imputation, an approach previously 
employed in literature to impute missing molecular data [van der Heijden, 2006; Leu et al., 
2013].  
 
4.3 METHODS 
4.3.1 Molecular methods 
Genomic DNA was previously extracted and purified from FFPE tissues of tumor [Richiardi et 
al., 2009] and correspondent NTAT [Richiardi et al., 2013] using the QIAamp ® DNA FFPE 
Tissue Kit (Qiagen, Hilden, Germany), and underwent fresh bisulfite modification using the 
Epitect Bisulfite Kit (Qiagen), along with fully methylated and unmethylated synthetic controls 
(CpGenomeTM universal methylated DNA and CpGenomeTM universal unmethylated DNA, 
Chemicon Co. Billerica, MA, USA.), that were included in each modification set. For 53 
patients DNA extracted from NTAT was not available, therefore we performed molecular 
analyses on their -80°C-stored bisulfite modified DNA saved by the previous research 
[Richiardi et al., 2013] 
After DNA conversion, analysis of LINE-1 (GenBank accession number X58075) promoter 
methylation status was performed using PyroMark Q24 MDx (Qiagen, Hilden, Germany). 
Primers, which amplify a 98-bp sequence of LINE-1 promoter containing three CpG sites 
(positions 819, 826 and 829), were designed outside the CpG sites using PyroMark Assay 
Design software version 2.0.6 (Qiagen) as follows: forward 5'-
TTTGAGTTAGGTGTGGGATATAGTT-3', reverse 5'-Biot-
CACCTAAAAAATCCAATCACTCC- 3' and sequencing 5’-
TTAGGTGTGGGATATAGTTT-3’. LINE-1 promoter methylation status was analyzed both 
in tumoral tissue and in NTAT. PCR reaction was performed in a total volume of 30 µl 
containing 1X buffer (KCl), 2 mM MgCl2, 0.8 mM dNTPs, 0.5 µM of each primer, 0.05 U Taq 
polymerase and 6 µl of bisulfite-converted DNA with the following cycling profile: 95°C for 
10’ followed by 45 cycles of denaturation at 95°C for 30’’, annealing at 55°C for 1’, extension 
at 72°C for 1’ and final extension at 72°C for 10’. The PCR product (20 µl) was added to 18 µl 
of distilled water and incubated under shaking with 40 µl of binding buffer and 2 µl of 
streptavidin-coated beads. Pyrosequencing reaction was performed in a total of 25 µl, including 
24.85 µl of 20 mM Tris-Acetate, 5 mM MgAc2 and 0.15 µl of 50 µM sequencing primer (final 
concentration 0.3 µM). Pyrosequencing methylation assay was created according to the 
manufacturer’s instruction and was set up using as the sequence to analyze and the 
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dispensation order C/TGTGGTGC/TGTC/TG and GTCGTAGATAGTCAGATC, respectively. 
Positive controls for fully methylated and fully unmethylated status were included in each 
pyrosequencing run. Methylation quantification was achieved using the provided software, and 
expressed for each DNA locus as percentage of methylated cytosines divided by the sum of 
methylated and unmethylated cytosines. 
 
4.3.2 Statistical analyses 
Correlation among the three CpG sites analyzed in LINE-1 promoter was high both in the 
tumor tissue and in the NTAT (pairways correlation coefficients were always > 0.83). We, 
therefore, combined the information for the three CpG sites using the mean level of 
methylation. Using factor analysis would have identified one principal component both in the 
tumor and in the NTAT explaining more than 90% of the variance. 
LINE-1 methylation in the tumor tissue and in the NTAT were treated as a continuous 
variables, with no logarithmic transformation as this transformation did not improve normality. 
We also created categorical variables with three levels of LINE-1 methylation. 
We used multivariate linear regression to estimate the association between selected 
characteristics and level of tumor tissue methylation in LINE-1. Normality was satisfied as 
indicated by tests based on skewness and Kurtosis (p=0.15) We used Cox proportional hazard 
regression models to estimate the hazard ratio (HR) of mortality from prostate cancer in 
association with LINE-1 methylation in the tumor tissue. Time from diagnosis was used as the 
time axis, while age and year of diagnosis were introduced as a continuous variable. The 
proportional hazard assumption was met as indicated by test based on Schoenfeld residuals (p 
=0.34). Models were always adjusted for the source of tumor tissue and progressively adjusted 
for tumor tissue methylation in APC and GSTP1 and Gleason score (variables categorized as 
shown in Table 4.1). Analogue analyses were performed by stratifying by tumor tissue and 
Gleason score (<8, 8+) respectively. 
Analyses of LINE-1 methylation in NTAT were restricted to biopsies and TURPs (105 patients 
out of 157). Since data on LINE-1 methylation level in NTAT from freshly-modified stored 
DNA were available only for 50 patients (~50%), we performed a multivariate imputation by 
chained equations (MICE) approach by assuming the data. Specifically, MICE approach was 
adopted assuming the data were missing at random [Rubin, 1976; Raghunatan and 
Bondarenko; 2007]. The imputation model involved regression of the LINE-1 methylation 
level in NTAT from freshly-modified stored DNA on diagnosis year, age at diagnosis, source 
of tissue, Gleason score, number of methylated genes out of APC and GSTP1 in the tumour 
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tissue and in the NTAT, LINE-1 tumor methylation level, LINE-1 methylation level in NTAT 
from stored bisulfite-modified DNA and  the survival data, including the event indicator, the 
cumulative hazard at the time of entry for the event actually experienced, and the difference 
between the estimated cumulative hazard at the exit time and that at entry [White and Royston, 
2009]. After fitting the imputation model, imputed values for the missing data were created 
using predictive mean matching.  
Similarly to the approach adopted for tumor tissue LINE-1 methylation, for each imputed 
dataset (n=20) we performed a multivariate linear regression to identify the factors associated 
with LINE-1 methylation in NTAT and Cox regression to estimate the association between 
NTAT LINE-1 methylation and prostate cancer-specific mortality. The survival analysis was 
further extended by estimating the association for different strata defined by Gleason score 
(<8,8+).  The obtained estimates were then combined into overall estimates, with standard 
errors, confidence intervals and p-values calculated using Rubin’s rule [Rubin, 1987]. Finally 
we compared the mean LINE-1 methylation level in NTAT and in tumor tissue restricted to 
subjects with biopsy or TURP by Wilcoxon test for paired data and the Spearman correlation 
coefficient. This analysis was furtherly stratified by tumor tissue.  
 
4.4 RESULTS 
Selected characteristics of the 157 prostate cancer patients are listed in Table 4.1. The majority 
of the study subjects have been diagnosed during the 1990s, with a median survival of 6.79 
years. Of the 128 deaths that occurred during the follow up, 43 were prostate cancer-specific. 
The source of tissue was equally distributed among biopsy, TURPs and radical prostatectomy. 
An higher proportion of both APC and GSTP1 promoter hypermethylation in tumor tissue 
(73.2%) can be noticed, while the higher proportion of the NTAT (42.7%) presents an 
unmethylated status.  
In Table 4.2 are reported the results of the analysis of association between selected 
characteristics of the tumor and LINE-1 methylation level measured in tumor tissue. Five 
patients have been excluded from this analysis due to missing data, thus leaving 152 prostate 
cancer patients for the following evaluations. LINE-1 methylation level was significantly 
higher in TURP tissue compared to biopsies and radical prostatectomies. Neither Gleason score 
nor hypermethylation of APC and GSTP1 in tumor tissue were associated with LINE-1 
methylation, although the direction of the association with gene-specific hypermethylation 
was, if anything, inverse.  
 48
There was a weak inverse association between LINE-1 methylation level and mortality from 
prostate cancer (HR2=1.07; 95% CI, 0.99-1.15, per each decrease in 1% of LINE-1 
methylation level) (Table 4.3), that  remained also in analyses stratified by source of tumor 
tissue (Table 4.4), indicating no heterogeneity in different type of samplings. 
When LINE-1 methylation value was categorized (Table 4.3) we found evidence, though not 
statistically significant, of increased risk for prostate cancer mortality especially for lower 
levels of LINE-1 methylation (methylation level <75%) (HR1=2.07; 95% CI: 0.71-6.02). This 
indication of association remained after adjustment for Gleason score and methylation of APC 
and GSTP1 (HR2=2.22; 95% CI: 0.75-6.58). 
When we stratified the analyses by Gleason score (<8 and 8+) (Table 4.5), LINE-1 methylation 
level remained higher in TURPs.We found an indication of inverse association between LINE-
1 hypomethylation and gene-specific hypermethylation, but only in high-risk prostate cancer 
patients (Gleason score ≥ 8) (adjusted β = -2.06; 95% CI: -5.17, 1.06) (Table 4.5). Inverse 
association beween LINE-1 methylation level and mortality from prostate cancer has been 
conserved only in analyses restricted to patients with Gleason score 8+, (HR2=1.12; 95% CI 
1.00-1.24, for each decrease in 1% of LINE-1 methylation level), with a stronger effect for low 
levels of LINE-1 methylation (LINE-1 methylation level <75% HR2=4.68; 95% CI 1.03-
21.34, adjusted); whereas LINE-1 methylation was not associated with prostate cancer-specific 
mortality of patients with Gleason score <8 (Table 4.6), as also well-described by the cubic 
splines (Figure 4.1). After exclusion of the 49 subjects who underwent prostatectomy, the 
analyses of association involving LINE-1 methylation level in NTAT have been performed on 
105 prostate cancer patients. As reported in Table 4.7, LINE-1 methylation level was 
significantly higher in NTAT dissected by TURPs, compared to that retrieved from biopsies 
(adjusted β = 3.71; 95% CI: 1.73, 5.69), and was associated neither with Gleason score nor 
with hypermethylation of APC and GSTP1.  
LINE-1 methylation level measured in NTAT was not associated with prostate cancer 
mortality (Table 4.8), and similar results were obtained in analyses stratified by source of 
tissue and by Gleason score (data not shown in tables). Mean LINE-1 methylation measured in 
tumor and in NTAT showed similar levels (79.20±4.13% and 79.27±3.87%, respectively), also 
when we stratified for source of tissue (data not shown in tables).  
 
4.5 DISCUSSION 
Hypermethylation of prostate cancer-related genes and LINE-1 hypomethylation, considered as 
surrogate of global DNA hypomethylation, have been reported as crucial epigenetic 
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mechanisms involved in development and progression of prostate cancer; therefore, they have 
been considered as potential biomarkers for prostate cancer diagnosis and prognosis [Valdés-
Mora and Clark, 2015]. In this study, we evaluated the prognostic potential of LINE-1 
methylation level, since multiple studies have repeatedly described its association with 
clinicopathological features of poor prognosis [reviewed by Zelic et al., 2015a].   
We found an indication of association between low levels of LINE-1 methylation measured in 
tumor tissue and mortality from prostate cancer, that in patients with high-risk prostate cancer 
(Gleason score 8+) became stronger. This association was not present neither in patients with 
Gleason score <8 nor when LINE-1 methylation was measured in the NTAT.  
Our results also pointed out a difference in LINE-1 methylation level among different sources 
of tissue. Both tumor tissue and NTAT retrieved from TURP showed higher mean percentages 
of LINE-1 methylation, compared to those measured in biopsies and radical prostatectomies, 
thus suggesting possible molecular differences among these types of samplings. In general, 
TURP procedure is performed to remove an obstruction of the lower urinary tract caused by a 
benign prostate hyperplasia, therefore it withdraws tissue portions from the anterior part of the 
prostatic gland through the urethra, namely transition zone [McVary et al., 2011]. 
Some previous investigations indicate that tumors originating from the transition zone show 
some differences in morphology [Greene et al., 1991], in biology (in terms of 
clinicopathological features) [Lee et al., 2015] and in molecular patterns, particularly for gene 
expression profiling [Sinnott et al., 2015] and for microRNA expression signature [Carlsson et 
al., 2013], compared to those growing in the peripheral zone. Now, our data suggest that 
tumors originating from the transition zone could also present a different epigenetic pattern, i.e. 
higher levels of LINE-1 methylation. A possible hypothesis could be that cancers arising from 
different zones of the prostatic gland may be differentialy susceptible to acquisition of genetic 
and epigenetic alterations, which might in part explain their consistent differences in prognosis, 
volume and other clinical variables, sugh as serum PSA level [Lee et al., 2015].  
Higher LINE-1 methylation levels detected in NTAT from TURPs should further support the 
hypothesis that morphologically normal transition zone has a different molecular pattern from 
peripheral tissue [Van der Heul-Nieuwenhuijsen et al., 2006; Noel 2008]. Therefore, we 
recommend to take into account this difference in studies aiming to measure LINE-1 
methylation level in prostate tissue: samplings coming from different zones should be 
considered separately in the analyses to avoid biases due to the source of tissue.   
This was also the reason why, from the analyses of association involving LINE-1 methylation 
level in NTAT, the 49 subjects who underwent radical prostatectomy have been excluded. This 
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was due to the high suspiction that the prostatectomy tissue contained an indistinguishable 
admixture of both transition and peripheral tissue, that have significantly different LINE-1 
methylation levels. Therefore, contamination of the prostatectomy by tissue coming from 
transitional zone could modify the levels of LINE-1methylation. This assumption was further 
confirmed by the quantification of the mean LINE-1 methylation level in NTAT retrieved by 
the prostatectomies, that was found to be intermediate between that measured in biopsies and 
that in TURPs (data not shown in tables). Since we could not exclude with certainty a possible 
contamination by transition tissue of the identified NTAT even re-evaluating the diagnostic 
slide, we had to exclude all the radical prostatectomies from the analyses. 
To our knowledge this is the first study that explored the relationship between LINE-1 
methylation status and mortality from prostate cancer. Our data support the possible 
involvement of global hypomethylation in tumor progression. There is an indication of  
association between LINE-1 methylation level and prostate cancer-specific mortality, that is 
already visible for intermediate levels of LINE-1 methylation (75-80%), but is particularly 
evident for drastic reductions in methylation percentage (<75%): this estimate is not 
statistically significant, probably because of the limitated sample size (N=152) and of the low 
number of events (N=18) present in the subgroup with marked LINE-1 hypomethylation. We 
could hypothesize that only a high derepression, via hypomethylation, of LINE-1 promoter 
could induce general disregulation involving chromosomal instability, reactivation of repeated 
sequences and oncogenes, as already demostrated in vivo [Howard et al., 2008]. The direction 
of this association has been conserved after adjusting for Gleason score, indicating that LINE-1 
hypomethylation might involved in prostate cancer progression through biological mechanisms 
that are in part different from that captured by the Gleason score. Furthermore, this effect on 
mortality from prostate cancer is relevant only for patients with high-risk prostate cancer: a 
possible explanation is that drastic LINE-1 hypomethylation is involved only in very later 
stages of the disease, even more late than those we previously thought, when many other 
molecular alterations (captured by the high Gleason score) have already occurred, thus leading 
to a wide dysregulation. On the contrary, in less aggressive tumors in which this global 
disregulation did not occurr, even low LINE-1 methylation level has any prognostic 
significance. According to this hypothesis, it might be speculated that low levels of LINE-1 
methylation are not able to distinguish indolent from aggressive cancer, rather they seem to 
have a potential in distinguish lethal prostate cancer from aggressive disease. Furthermore, the 
observation that even low levels of LINE-methylation in NTAT were not associated with 
mortality from prostate cancer give further strenght to the hypothesis that LINE-1 
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hypomethylation is involved only in very later stages of the disease. Also, our results suggest 
that gene-specific hypermethylation and global DNA hypomethylation coexist in tumor tissue, 
expecially in the most aggressive, but not in NTAT.  Our data reinforce the previously 
proposed model of prostate cancer as the results of an epigenetic catastrophe [Perry et al., 
2010], where not only hypermethylation of specific genes involved in prostate tumorigenesis 
contributes to disease progression, but also global hypomethylation may play a relevant role.  
In conclusion, our data suggest that in prostate cancer gene-specific hypermethylation and 
global DNA hypomethylation coexist, expecially in high-grade tumors. Our results did not 
suggest that LINE-1 hypomethylation is an early event in prostate tumor: rather, LINE-1 
hypomethylation seems to be a late epigenetic mechanism implicated in prostate cancer 
progression. Specifically, low levels of LINE-1 methylation appear to have a strong effect on 
prostate cancer-specific mortality only in patients with high Gleason score. For these reasons, it 
could be speculated that LINE-1 hypomethylation might be useful to distinguish into the group 
of the high-risk prostate cancers those with high risk of death.  
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4.6 TABLES AND FIGURES 
 
Figure 4.1. Association between LINE-1 methylation level in tumor tissue and mortality from 
prostate cancer by stratifying for Gleason score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cubic splines with four internal knots are defined by the 20,40,60,80 percentile. Results have been reported 
graphically using the methylation value of 80% as the reference.  
Estimates have been adjusted for age at diagnosis, year of diagnosis and source of tumor tissue.  
 
(Fiano et al., in preparation) 
Gleason score < 8 Gleason score 8+ 
ORs 95% CIs
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Table 4.1. Selected characteristics of the study patients. 
 
Characteristics Number (%) 
Year of diagnosis   
1982-1988 28 (17.8%) 
1993-1996 129 (82.2%) 
Range survival time (years) 0.03-24.11  
Median survival time (years) 6.79  
Age at diagnosis (years)   
40-64 26 (16.6%) 
65-69 35 (22.3%) 
70-74 40 (25.5%) 
75+ 56 (35.7%) 
Mortality   
Overall 128 (81.5%) 
From prostate cancer 43  
From other causes 85  
Source of tumour tissue   
Biopsy 54 (34.4%) 
TURP 54 (34.4%) 
Radical prostectomy 49 (31.2%) 
Gleason score   
<7 59 (37.6%) 
7 41 (26.1%) 
≥8 57 (36.3%) 
N. genes methylated in prostatic tumour tissue (out of APC and GSTP1) 
0 11 (7.0%) 
1 31 (19.8%) 
2 115 (73.2%) 
N. genes methylated in NTAT (out of APC and GSTP1) 
0 67 (42.7%) 
1 45 (28.7%) 
2 45 (28.7%) 
 
 (Fiano et al., in preparation) 
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Table 4.2. Selected characteristics in association with LINE-1 methylation in the tumor tissue. 
 
Characteristic Mean Line-1 (Sd) Coefficient* 95% CI 
All patients (N=152) 78.55 (4.29) - - 
Source of tumor tissue    
Biopsy 77.52 (4.32) Ref  
TURP 80.72 (3.42) 2.91 1.23, 4.59 
Radical prostectomy 77.32 (4.26) -0.64 -2.38, 1.11 
Gleason score    
<7 77.95 (3.63) Ref  
7 78.26 (4.89) 0.37 -1.34, 2.08 
≥8 79.36 (4.29) 0.41 -1.21, 2.04 
APC and GSTP1 methylation in tumour tissue    
Continuous: 0,1,2 methylated genes 78.55 (4.29) -0.37 -1.54, 0.80 
 
*Adjusted for age at diagnosis, year of diagnosis, and variables listed in the Table.   
 
(Fiano et al., in preparation) 
 
Table 4.3. LINE-1 methylation level in tumor tissue in association with mortality from prostate 
cancer. 
 
LINE-1 methylation Prostate cancer deaths (N) HR1 (95% CI)a HR2 (95% CI)a 
Decrease in 1% methylation 41 1.05 (0.97-1.14) 1.07 (0.99-1.15) 
Categorical    
<75 18 2.07 (0.71-6.02) 2.22 (0.75-6.58) 
75-80 6 1.47 (0.73-2.95) 1.60 (0.81-3.18) 
80+ 17 1.00 1.00 
 
a HR1, hazard ratio adjusted for age and year of diagnosis and source of tumor tissue; HR2, adjusted as HR1, 
Gleason score and APC and GSTP1 methylation in the tumor tissue; CI, confidence intervals. 
 
(Fiano et al., in preparation) 
 
Table 4.4. LINE-1 methylation level in tumor tissue in association with mortality from prostate 
cancer, stratified by type of tumor tissue. 
 
a HR1, hazard ratio adjusted for age and year of diagnosis; HR2, adjusted as HR1, Gleason score and APC and 
GSTP1 methylation in the tumor tissue; CI, confidence intervals. 
 
(Fiano et al., in preparation) 
LINE-1 methylation Prostate cancer deaths (N) HR1 (95% CI)
a HR2 (95% CI)a 
Biopsy    
Decrease in 1% methylation 14 0.98 (0.87-1.11) 1.04 (0.92-1.18) 
Radical prostatectomy    
Decrease in 1% methylation 6 1.09 (0.95-1.26) 1.09 (0.95-1.26) 
TURP    
Decrease in 1% methylation 21 1.09 (0.89-1.33) 1.10 (0.89-1.35) 
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Table 4.5. Selected characteristics in association with LINE-1 methylation in the tumor tissue 
stratified by Gleason score. 
 
Characteristic Mean Line-1 (Sd) Coefficient* 95% CI 
Patients with Gleason score <8 (N=96) 78.08 (4.17) - - 
Source of tumor tissue    
Biopsy 77.38 (4.31) Ref  
TURP 80.61 (3.08) 3.04 0.80, 5.28 
Radical prostectomy 77.27 (4.09) -0.47 -2.50, 1.57 
APC and GSTP1 methylation in tumour tissue    
Continuous: 0,1,2 methylated genes 78.08 (4.17) -0.03 -1.28, 1.22 
    
Patients with Gleason score 8+ (N=56) 79.36 (4.40) - - 
Source of tumor tissue    
Biopsy 77.83 (4.46) Ref  
TURP 80.80 (3.70) 2.57 -0.21, 5.35 
Radical prostectomy 77.50 (5.11) -2.03 -6.06, 2.00 
APC and GSTP1 methylation in tumour tissue    
Continuous: 0,1,2 methylated genes 79.36 (4.40) -2.06 -5.17, 1.06 
 
*Adjusted for age at diagnosis, year of diagnosis, and variables listed in the Table.   
 
(Fiano et al., in preparation) 
 
 
Table 4.6. LINE-1 methylation level in tumor tissue in association with mortality from prostate 
cancer stratified by Gleason score. 
 
LINE-1 methylation Prostate cancer deaths (N) HR1 (95% CI)a HR2 (95% CI)a 
Patients with Gleason score<8 (N=96)    
Decrease in 1% methylation 13 0.98 (0.85-1.13) 0.99 (0.86-1.13) 
Categorical    
<75 6 0.91 (0.15-5.38) 0.83 (0.14-4.96) 
75-80 5 0.74 (0.20-1.72) 0.67 (0.17-2.59) 
80+ 2 1.00 1.00 
    
Patients with Gleason score 8+ (N=56)    
Decrease in 1% methylation 28 1.11 (1.00-1.23) 1.12 (1.00-1.24) 
Categorical    
<75 11 4.33 (1.02-18.39) 4.68 (1.03-21.34) 
75-80 13 1.98 (0.85-4.64) 2.03 (0.85-4.86) 
80+ 4 1.00 1.00 
 
a HR1, hazard ratio adjusted for age and year of diagnosis and source of tumor tissue; HR2, adjusted as HR1 and 
APC and GSTP1 methylation in the tumor tissue; CI, confidence intervals. 
 
(Fiano et al., in preparation) 
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Table 4.7. Selected characteristics in association with LINE-1 methylation in the NTAT 
 
Characteristic Mean Line-1 (Sd)* Coefficient* (95% CI) 
All patients (N=105) 79.27 (3.87) - - 
Source of tumor tissue    
Biopsy 77.37 (3.32) Ref  
TURP 81.12 (3.48) 3.71 1.73, 5.69 
Gleason score    
<7 78.04 (3.58) Ref  
7 79.67 (3.98) 1.19 -1.27, 3.65 
≥8 79.95 (3.89) 0.34 -1.75, 2.43 
APC and GSTP1 methylation in NTAT    
Continuous: 0,1,2 methylated genes 79.20 (4.13) 0.33 -0.89, 1.56 
 
*Adjusted for age at diagnosis, year of diagnosis, and variables listed in the Table.   
 
(Fiano et al., in preparation) 
 
 
 
 
Table 4.8. LINE-1 methylation in the NTAT and mortality from prostate cancer. 
 
LINE-1 methylation Prostate cancer deaths (N) HR1 (95% CI)a HR2 (95% CI)a 
Decrease in 1% methylation 37 0.96 (0.83-1.12) 0.97 (0.84-1.12) 
Categorical N*   
<1st tertile (<75) 3.45 0.57 (0.05-6.60) 0.71 (0.06-7.89) 
1st to  2nd tertile (75-80) 17.4 0.91 (0.33-2.47) 0.79 (0.30-2.09) 
2nd+ tertile (80+) 16.15 1.00 1.00 
 
a HR1, hazard ratio adjusted for age and year of diagnosis and source of tumor tissue; HR2, adjusted as HR1, 
Gleason score and APC and GSTP1 methylation in the NTAT  tissue; CI, confidence intervals. 
* Failure’s average among imputed datasets. 
 
(Fiano et al., in preparation) 
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5. STUDY 3 
“EVALUATION OF DNMT3b VARIANTS IN ASSOCIATION WITH GENE-
SPECIFIC HYPERMETHYLATION, GLOBAL DNA HYPOMETHYLATION, 
GLEASON SCORE AND PROSTATE CANCER”  
 
In this study we performed the genotyping of three selected DNMT3b genetic variants on two 
cohorts of prostate cancer patients with two specific aims: 
1. To assess the associations between DNMT3b polymorphisms and LINE-1 methylation 
level, as well as with APC and GSTP1 hypermethylation, both measured in tumour 
tissue, to understand if these variants could affect the methylation pattern in prostate 
cancer cells; 
2. To evaluate the direct effect of DNMT3b polymorphisms on tumour aggressiveness (as 
measured by the Gleason score) and on mortality from prostate cancer, to understand 
their possible involvement in prostate cancer progression.  
 
The study was approved by the Local Ethical Committee. 
 
5.1 PRELIMINARY DATA 
In our ongoing project on epigenetic alterations and prostate cancer we have explored, in a 
large cohort of consecutive prostate cancer patients (for cohort characteristics see section 4.1), 
the effect of DNMT3b variant rs406193 (C>T) on methylation status of the promoter of APC 
and GSTP1 in tumor tissue, on the Gleason score of the tumor and on mortality from prostate 
cancer.  
Specifically, to better understand the possible interplay between the variables under study, a 
model of causal relationships has been proposed, under some specific assumptions: 
i) selected variants can affect DNMT3b enzymatic activity; 
ii) DNMT3b activity can affect methylation status in tumor tissue; 
iii) aberrant methylation status can affect tumor morphology and thus the Gleason score; 
iv) aberrant methylation affects mortality both directly and via Gleason score.  
Despite we did not found evidence of association between T carriers and number of 
hypermethylated genes, however, T carriers had a reduced risk of a Gleason score 8+ 
(OR=0.57, 95 % CI 0.39-0.85), and a hazard ratio of 0.81 (0.61-1.09) of dying from prostate 
cancer. These results not only provided new insights on the involvement of  DNMT3b variants 
in prostate cancer progression, but they also suggested that to provide a reliable estimate of the 
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association between hypermethylation tumor tissue and prostate cancer mortality it is very 
important to consider the possible causal relationships between the involved variables [Gillio 
Tos et al., 2012]. 
In the current study, to increase the complexity of this model, we analysed three additional 
DNMT3b polymorphisms on two cohorts of patients belonging to the original cohort of 459 
subjects with prostate cancer described in section 4.1. 
 
5.2 STUDY DESIGN AND CHARACTERISTICS OF THE TWO COHORTS  
This cohort study was carried out on two cohorts of prostate cancer patients for validation 
purposes. Subjects of these two cohorts come from the cohort of 459 consecutive prostate 
cancer patients who underwent biopsy, radical prostatectomy or TURP between 1982 and 
1996, at the pathology ward of the San Giovanni Battista Hospital, Turin, Italy, described 
previously in details (Section 4.1). The first cohort, hereafter referred as “adjacent tissue 
cohort”, is composed by the same prostate cancer patients involved in the STUDY 2 (for 
summary of the characteristics of the cohort see section 4.2). The second cohort, hereafter 
referred as “1980-biopsy cohort” included prostate cancer patients diagnosed during the 1980s 
at the San Giovanni battista Hospital, Turin, who underwent only prostate biopsy procedure, 
hence have been excluded from the STUDY 2. While for patients of the 1980-biopsy cohort 
only one type of sampling was available (i.e. biopsies), for the adjacent tissue cohort biopsy, 
TURP and radical prostatectomy samples for patients diagnosed during the 1990s, and TURPs 
and radical prostatectomies for those diagnosed during the 1980s were available. Clinical data 
for each patient have been listed before (section 4.1). For both cohorts methylation data of 
APC, GSTP1 and RUNX in tumor tissue have been provided by a previous study [Richiardi et 
al., 2009]. In addition, only for adjacent tissue cohort patients, LINE-1 methylation data in 
tumor tissue were available (STUDY 2).  
 
5.3 METHODS 
5.3.1 Selection of SNPs for genotyping 
In our first study [Gillio Tos et al., 2012] the polymorphism rs406193 was chosen on the basis 
of the association of its variant T with a reduced risk of breast and colorectal cancer in women. 
DNMT3b maps at locus q11.2 on chromosome 20 and several polymorphisms affecting its 
expression, DNA methylation activity and suceptibility to cancer have been identified 
[reviewed by Duan et al., 2015]. The most extensively studied DNMT3b polymorphism is 
rs2424913 (-149C → T), an intron variant located -149 bp from the transcription start site 
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(TSS). The T variant has been shown to result in a 30% increase in promoter activity in lung 
cancer cells [Shen et al., 2002], and also in pancreatic cancer cells (3.8-fold), thus enhancing 
its transcription [Xiao et al., 2011] and inducing methylation changes at the promoters of 
different genes [Kawakami et al., 2006] Furthermore, carriers of the T allele have been 
reported to have significantly increased risk of several types of cancers [Duan et al., 2015], and 
it has been also correlated to poor prognosis for head and neck cancer [Azad et al., 2012]. 
However, as recently reviewed, published data on the role of rs2424913 in cancer susceptibility 
remain inconclusive [Zhu et al., 2015].  
Rs1569686 (G → T) is an intron variant mapping in the promoter of DNMT3b, -579 bp from 
the TSS of exon 1B. The allele G has been shown to decrease susceptibility to colorectal, 
gastric and lung cancer, and to increase susceptibility to acute myeloid leukemia [Duan et al., 
2015]. Furthermore, it has been associated with poor prognosis for gastric cancer [Wang et al., 
2015]. The functional role of the DNMT3b rs1569686 polymorphism is not yet completely 
elucidated. Some authors suggest that it can directly impair promoter activity and gene 
expression levels by inducing changes in transcription factor binding affinity, and others 
observed a linkage disequilibrium (LD) between this SNP and other DNMT3b promoter 
polymorphisms, which have been functionally associated with promoter activity and gene 
expression levels. These observations suggest that this polymorphism might either have a 
functional role, or be a tag SNP of other functional haplotypes [Coppedè et al., 2013].  
The third selected SNP, rs2424932 (G→A), is a 3’ UTR variant repeatedly reported to increase 
susceptibility to developing schizophrenia and to suicide attempts in psychiatric patients. Its 
role in cancer has been poorly explored, however, it has been chosen as a Tagging SNP with 
predicted functionality in multiple studies [Mostowska et al., 2013; Murphy et al., 2013]. 
In summary, we performed the genotyping of three new SNPs in the DNMT3b gene, 
rs2424913, rs1569686 and rs2424932, located in noncoding regions: although they do not 
translate protein, these regions may have a predictive role in gene expression and transcription 
regulation. Indeed, apart from their correlations with a wide range of cancers and with other 
human pathologies, the previously described evidences suggest that these polymorphisms 
might be potentially able to change the DNMT3b gene expression by acting on the promoter 
activity and on the transcription factor binding, thus altering the enzymatic levels of the 
methyltransferase. Futhermore, these SNPs show strong evidences of historical recombination 
with the rs406193 polymorphisms, already studied by our group [Gillio tos et al., 2012].  
Location of the selected variants along the DNMT3b gene is shown in Figure 5.1.  
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5.3.2 Molecular analyses  
Genomic DNA extracted from FFPE blocks of prostate cancer patients of the two cohorts was 
already available from previous studies [Richiardi et al., 2009; Gillio Tos et al., 2012]. 
Genotyping of the three DNMT3b SNPs was carried on by pyrosequencing analysis using 
PyroMark Q24 MDx (Qiagen, Hilden, Germany). Primers for genotyping of each SNP, have 
been designed using PyroMark Assay Design software version 2.0.6 (Qiagen). Primer 
sequences used to analyze each SNP are reported in Table 5.1.We performed PCR reaction in a 
total volume of 30 µl containing 1X buffer (KCl), 2 mM MgCl2, 0.8 mM dNTPs, 0.5 µM of 
each primer, 0.05 U Taq polymerase and 1-2 µl of genomic DNA with the following cycling 
profile: 95°C for 10’ followed by 45 cycles of denaturation at 95°C for 30’’, annealing for 30’’ 
at 62°C for rs2424913, at 54°C for rs1569686 and at 61°C for rs2424923, extension at 72°C 
for 1’ and final extension at 72°C for 10’. The PCR product (20 µl) was added to 18 µl of 
distilled water and incubated under shaking with 40 µl of binding buffer and 2 µl of 
streptavidin-coated beads. Pyrosequencing reaction was performed in a total of 25 µl, including 
24.85 µl of 20 mM Tris-Acetate, 5 mM MgAc2 and 0.15 µl of 50 µM sequencing primer (final 
concentration 0.3 µM). Pyrosequencing genotyping assays were created according to the 
manufacturer’s instruction setting a SNP assay for each polymorphism. Sequence to analyze 
and dispensation order used to analyze each SNP are reported in Table 5.1. 
 
5.3.3 Statistical analyses 
All analyses were first conducted in the 1980s biopsy cohort and then replicated in the adjacent 
tissue cohort (except for the analysis on LINE-1 methylation level, which was performed only 
in the adjacent tissue cohort). 
For each of the three DNMT3b variants Hardy-Weinberg equilibrium was tested [Cleves, 
2005], and the R-squared (R2) statistics of linkage disequilibrium was calculated and plotted 
using pwld command (available from http://www-gene.cimr.cam.ac.uk/clayton) for both 
cohorts. We inferred haplotypes of DNMT3b by using the PHASE algorithm (version 2.1, 
Matthew Stephens Lab, University of Chicago, Chicago, IL, USA).  
We used dominant and recessive models of inheritance to estimate the associations between 
single genotypes and haplotypes and different outcomes: i) number of methylated genes; ii) 
LINE-1 methylation level; iii) Gleason score; iiii) prostate cancer mortality. We used ordinal 
logistic regression to estimate the odds ratio and corresponding 95% confidence intervals of the 
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effect of each DNMT3b variant on the number of methylated genes. We used three levels for 
the dependent variable (0–1, 2 or 3 methylated genes out of APC, GSTP1, and RUNX3), and 
the odds ratios estimated in this model should be interpreted as the effect of single genetic 
variants/haplotypes on the increase in the number of methylated genes.  
Linear regression was used to estimate the coefficients and corresponding 95% CIs of the 
effect of each SNP/haplotype on the LINE-1 methylation level: as LINE-1 methylation was 
analyzed at more than 1 CpG site, mean methylation level across the CpG sites was used in the 
analyses. Logistic regression was used to estimate the OR and the corresponding 95% CIs of 
having a high Gleason score (8+). Since the number of methylated genes was assumed to be an 
intermediate variable in the path between the DNMT3b variants and Gleason score, we did not 
adjusted for it in this analysis. 
We evaluated the effect of DNMT3b genetic variants on prostate cancer mortality by using a 
Cox regression model to estimate hazard ratios and corresponding 95% CIs. The proportional 
hazard assumption was checked by the formal test based on Schoenfeld’s residuals. The 
number of methylated genes and Gleason score were not included in the analysis as it was 
assumed that they were intermediate variables in the path between the DNMT3b variants and 
prostate cancer-specific mortality. 
Age at diagnosis, calendar year of diagnosis and source of tumor tissue (biopsy, TURP or 
prostatectomy) were included as potential confounders when necessary. No correction for 
multiple comparisons was performed.  
All statistical analyses were conducted using STATA 12 (STATA Corporation, College 
Station, TX, USA).  
 
5.4 RESULTS 
Characteristics of the prostate cancer patients involved in this study are reported in Table 5.2. 
The 1980-biopsy cohort included 176 patients with prostate cancer diagnosed during the 1980s 
who received prostate biopsy, while the adjacent tissue cohort (N=157) is composed by subject 
with prostate cancer diagnosed between 1982 and 1996 who received prostate biopsy (only 
those diagnosed during the 1990s), TURP or radical prostatectomy. Patients of the adjacent 
tissue cohort are younger at diagnosis and have a longer median survival time. In the 1980-
biopsy cohort, out of 174 deaths, 111 were due to prostate cancer, while in the adjacent tissue 
cohort prostate cancer-specific mortality occurred in 43 out of 129 total deaths.  
Genotyping was unsuccessful for 4 patients for the rs1569686, for 3 patients of the rs2424913 
and for 7 patients of the rs2424932. Genotyping success rate ranged from 97,8 to 99%. All the 
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polymorphisms are in Hardy-Weinberg equilibrium in both cohorts (Table 5.3), and the LD 
relationships between the genetic variants, along with their recombination rates, are reported in 
Figure 5.2. rs1569686 and rs2424913 demonstrated strong LD  both in the 1980-biopsy cohort 
(r2=0.75) and in the adjacent tissue cohort (r2=0.81).   
Table 5.4 reports the results of the analysis of association between genotypes and haplotypes of 
DNMT3b and hypermethylation of selected genes in tumor tissue. Single polymorphisms did 
not give statistically significant results, however in the 1980 biopsy cohort we found a strong 
effect of the haplotype GCG in homozygosis in increasing the number of hypermethylated 
genes (OR=12.86; 95% CI 1.41-117.16), although the confidence interval was very large. 
Adjustment for age at diagnosis and year of diagnosis did not substantially alter the results 
(data not shown in tables).  
Association between DNMT3b variants and LINE-1 methylation level was performed only 
within the adjacent tissue cohort: genotype AA of the polymorphism rs2424932, compared to 
AG+GG, was strongly associated with higher LINE-1 methylation levels (β=1.72; CI 95% 
0.07-3.37, fully adjusted), whereas allele T of polymorphism rs1569686 in homozygosis, as 
well as TTG haplotype in homozygosis, show a weak inverse association with LINE 
methylation level. Moreover, subjects carrying two copies of haplotype GCA have higher 
LINE-1 methylation levels (β=2.32; CI 95% 0.56-4.08), adjusted for source of tissue and year 
of diagnosis) (Table 5.5). Further adjustment for age at diagnosis gave similar results (data not 
shown in tables). 
Neither single DNMT3b genotypes nor haplotypes are associated with Gleason score of the 
tumor (Table 5.6).  
In prognostic analyses (Table 5.7), any polymorphism showed noteworthy effects, apart from a 
weak inverse association between allele A of rs2424932 and prostate cancer mortality, 
noticeable in both cohorts. In haplotype analysis, GCA carriers (in both inheritance models) 
show a slightly decreased risk of dying for prostate cancer in both cohorts. Furthermore, 
carriers of two copies of haplotype GCG have showed a more than three-times higher risk of 
dying from prostate cancer, and this strong effect was replicated in both cohorts (HR=3.74; 
95% CI 1.33-10.55 for the 1980-biopsy cohort; adjusted HR=3.04; 95% CI 1.16-7.94 for the 
adjacent tissue cohort; adjusted for source of tissue, age at diagnosis and year of diagnosis) 
(Table 5.7). Analyses restricted to the first 5 years of follow-up gave similar results (data not 
shown).  
Finally, we used the database of the Prostate Adenocarcinoma (TCGA, provisional) study 
available through the cBioPortal (http://www.cbioportal.org) to perform an explorative analysis on 
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the association between DNMT3b expression levels and prostate cancer survival. The results 
obtained pointed out a strong association between DNMT3b expression level and prostate 
cancer-free survival (Logrank Test P-Value: 2.968e-4).  
 
5.5 DISCUSSION 
In this study, we evaluated selected genetic variants in the gene codifying for the DNA 
methyltransferase 3b in relation with Gleason score and prostate cancer prognosis, as well as 
with gene specific hypermethylation and global DNA hypomethylation measured in prostate 
tissue. Specifically, we wanted to assess the direct effect of selected variants on mortality from 
prostate cancer (irrispectively of the aberrant methylation status in tumor tissue), as well as to 
evaluate their effect on aberrant methylation (considered as intermediate variable) that, in turn, 
affect prostate cancer prognosis. Assumed causal relationships between the variables 
considered in this study have been previously discussed [Gillio-Tos et al., 2012].  
We selected three polymorphisms mapping in DNMT3b gene sequence: our selection included 
both putative functional polymorphisms (rs1568696 and rs2424913) and a Tag-SNP 
(rs2424932), a strategy that has been already used in previous researches [Potter et al., 2013]. 
The putative functional SNPs, apart from their previously reported associations with other 
kinds of cancer, have been chosen because of their potential effect on DNMT3b gene 
transcription. The underlying hypothesis is that these variants could alter the transcription of 
the DNMT3b gene, thus affecting its expression levels and, in turn, influencing the enzyme 
production. Significantly higher expression levels of DNMT3b, as well as higher protein 
levels, has been repeatedly detected in cancerous over benign tissues [Hoffmann et al., 2007; 
Kobayashi et al., 2011; Gravina et al., 2013; Basu et al., 2015]. In addition, higher levels of 
expression of DNMT3b have been measured in high-tumorigenic prostate cancer cell lines 
compared to low-tumorigenic cells [Gravina et al., 2013], thus suggesting a possible 
association between increased DNMT3b expression and tumor progression. In order to 
corroborate these evidences, we used freely available DNMT3b expression data and survival 
data of a dataset of prostate cancer patients, accessible via the cBioPortal for Cancer 
Genomics. cBioPortal is a very useful resource that stores genomic data from large scale and 
integrated cancer genomic data sets, also allowing explorative data analyses. Specifically, we 
used dataset provided by the Prostate Adenocarcinoma (TCGA, Provisional) study: for 213 
patients of this cohort both DNMT3b mRNA expression data and disease-free survival data 
were available. We found that prostate cancer patients with DNMT3b overexpression have a 
significantly shorter disease-free survival compared to subjects with normal levels of the 
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enzyme, thus strengthening the hypothesis of a relationship between DNMT3b overexpression 
and prostate cancer prognosis.   
We evaluated if selected variants in DNMT3b gene are associated with prostate cancer-specific 
mortality in order to assess their direct effect on the outcome. GCG haplotype in homozygosis 
is strongly associated with a three-times higher risk of dying from prostate cancer, and this 
strong effect was replicated in both cohorts with a very similar magnitudo of the effect, 
although the confidence intervals of these estimates were wide. Our results suggest that 
prostate cancer-specific mortality may be affected by DNMT3b variants but, since the effects 
of single SNPs on prostate cancer prognosis seem to be too little to be detectable, a 
considerable effect could be obtained only in the form of the haplotype.  
Gene-specific hypermethylation and global DNA hypomethylation have been widely studied in 
prostate cancer, and their strong association with tumor development and progression have 
been repeatedly observed. Nevertheless, the determinants of aberrant methylation are still 
poorly understood in this type of cancer. Since DNMT3b enzyme is considered to have a 
pleiotropic effect and its overexpression was correlated to hypermethylation of several tumor-
related genes [Roll et al., 2008; Amara et al., 2010], in our analyses we did not consider the 
effect of the genetic variants on the hypermethylation of each gene separately, but, collectively, 
on increasing number of hypermethylated genes in tumor tissue.  
GCG haplotype in homozygosis was strongly associated with increasing number of 
hypermethylated genes in 1980-biopsy cohort. Hypothesizing that this combination of genetic 
variants in DNMT3b sequence could cause an higher level of synthetized enzyme and, 
therefore, higher methylation levels in the promoter of the genes specifically involved in 
prostate cancer, it is plausible that the effect of GCG haplotype on prostate cancer mortality 
may be explainable by its effect on gene-specific hypermethylation. In the adjacent tissue 
cohort the association, although outlined, is very weak, likely due to the lower prevalence of 
hypermethylation in tumor tissue of these patients. We have data on the methylation status of 
only three genes in tumor tissue, likely adding other genes to this analysis these estimates 
might be more consistent. A good strategy to expand and to validate this analysis could be to 
draw, from the public databases, genotyping data and methylation data of other genes obtained 
on large cohorts of prostate cancer patients.  
We evaluated the effect of DNMT3b variants also on LINE-1 methylation levels, since a 
significative correlation between DNMT3b expression levels and global hypermethylation in 
prostate tumor has been found [Kobayashi et al., 2011]. Interestingly, GCG haplotype has no 
effects on LINE-1 methylation, whereas opposite effects were noted for the GCA haplotype, 
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which is strongly associated with higher LINE-1 methylation levels when present in 
homozygosis. We could speculate that different DNMT3b haplotypes could exert different 
effects on DNMT3b gene expression levels, thus modulating the enzyme production and, as a 
consequence, leading to different effects on the methylation pattern. Specifically, since 
DNMT3b is preferentially a de novo methyltransferase but its role in the maintenance of the 
global DNA methylation pattern during each cellular replication was also demonstrated, we 
could hypothesized that a possible increased expression induced by GCG haplotype might have 
an effect on gene-specific hypermethylation, rather that in maintaining LINE-1 methylation at 
consistently high levels, while normal levels of enzyme (possibly induced by GCA haplotype) 
might not exert this de novo gene-specific effect but only a maintenance effect. This is in part 
supported by previous works that have demonstrated that DNMT3b overexpression induces 
DNA methylation in some CpG islands in a non-random manner [Linhart et al., 2007; 
Kobayashi et al., 2011]; analogously, depletion of DNMT3b have been reported to affect 
locus-specific DNA methylation, thus increasing the expression of distinct set of genes 
[Yaqinuddin et al., 2008; Wang et al., 2015]. Obviously, further investigations and 
experimental assays are needed to prove our hypothesis. 
Our data show that the opposite effects observed for these different combinations of  DNMT3b 
genotypes might be partly due to the polymorphism rs2424932. The effect of this genetic 
variant on cancer risk has been poorly investigated, and functional assays to test its 
consequence on enzyme expression and activity are still lacking; however, it could have 
functional significance. An in silico tool (SNP Function Prediction (FuncPred) 
(snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm)) revealed that presence of A allele adds an 
additional regulation to the gene through influencing hsa-mir-920 binding [Saradalekshmi et 
al., 2014]; also, the A/G polymorphism at this locus is predicted to create alternative 
transcription factor binding sites [Murphy et al., 2013].  
In conclusion, in two indipendent cohorts of prostate cancer patients, we have found that an 
haplotype of the DNMT3b gene, when present in homozygosis, is strongly associated with 
mortality from prostate cancer. The same haplotype showed, in one of the two cohorts, to 
increase the gene-specific hypermethylation, leading to the hypothesis that different DNMT3b 
haplotypes could have different effects on gene expression and, consequently, on the enzyme 
production and activity. This hypothesis need to be tested in further investigations. 
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Figure 5.1. Graphical view of the location of the SNPs genotyped in the current study along 
the DNMT3b gene sequence 
 
 
 
 
 
 
 
 
 
 (Source: http://www.ncbi.nlm.nih.gov/variation/view/) 
 
 
 
 
Figure 5.2. Linkage Disequilibrium plot for the polymorphisms under study in the 1980-
biopsy cohort (left) and in the adjacent tissue cohort (right).  
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Figure 5.3. Association between DNMT3b expression level and disease-free survival in a 
cohort of patients with prostate adenocarcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: pubblicly available data at cBioPortal for Cancer Genomics, Prostate Adenocarcinoma (TCGA, 
provisional) study. z-score threshold: ± 1.5. 
 
 
 
 
Table 5.1. List of primers, sequence to analyze and dispensation order for each genotyped 
DNMT3b polymorphisms by pyrosequencing 
 
 
 
 rs2424913 rs1569686 rs2424932 
Primer FW GCCACCTGAAGGCCTAATC [Bnt] CAAAGGCAAGTGACTTGGAA TTTTGTAGACAAGTATGGCTCCTC 
Primer Rev [Bnt]GACACTCACTGGGCCTTA AGTAAAAAACTTCAGGGCATAAAT [Bnt] GCTCCTTGCTTCACACTCCT 
Primer Seq GGCCCCGCCAGACCC AAACTTCAGGGCATAAAT CAAGTATGGCTCCTCC 
Sequence to 
analyze 
C/TAGGCCTCCAG CCCA/CGCTGAAACCGA A/GTATCTCCC 
Dispensation 
Order 
GCTAGCTC GCCAGCTGA CAGTATCT 
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Table 5.2. Selected characteristics of the two cohorts of prostate cancer patients  
 
 
#Methylation of GSTP1, APC and RUNX in tumor tissue 
 
 
Characteristics 1980-biopsy cohort Adjacent tissue cohort 
 N % N % 
Year of diagnosis     
1982-1988 176 100% 28 17.8% 
1993-1996 0 0 129 82.2% 
Range survival time (years) 0.02-26.8  0.03-24.11  
Median survival time (years) 3.21  6.79  
Age at diagnosis (years)     
40-64 33 19.0% 26 16.6% 
65-69 23 13.1% 35 22.3% 
70-74 36 20.5% 40 25.5% 
75+ 82 46.6% 56 35.7% 
Mortality     
Overall 174 98.3% 129 81.5% 
From prostate cancer 111  43  
From other causes 63  86  
Source of tumour tissue     
Biopsy 174 100% 53 33.8% 
TURP 0 - 55 35.0% 
Radical prostatectomy 0 - 49 31.2% 
Gleason score     
<7 23 13.7% 59 37.6% 
7 66 38.7% 41 26.1% 
≥8 80 47.6% 57 36.3% 
Missing 7 - - - 
Number of methylated genes#     
0 2 1.27 18 12.68 
1 35 22.29 44 30.99 
2 79 50.32 58 40.85 
3 41 26.11 22 15.49 
Missing 19 - 15 - 
LINE-1 mean (SD) 78.55 (4.29) - 
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Table 5.3. Tests for Hardy-Weinberg Equilibrium  
 
Polymorphism 1980-Biopsy cohort (N=174) Adjacent tissue cohort (N=157)
 P value P value 
rs1569686 0.52 0.43 
rs2424913 0.87 0.14 
rs2424932 0.28 0.61 
 
 
 
 
Table 5.4. Analysis of association between genotypes and haplotypes of DNMT3b and number 
of hypermethylated genes measured in tumor tissue 
 
Variant 1980-biopsy cohort Adjacent tissue cohort 
 N° of hypermethylated genes N° of hypermethylated genes 
 OR (95% CI) OR (95% CI) OR (95% CI)b OR (95% CI)b 
 Dominant Recessive Dominant Recessive 
Genotype     
rs1569686_T 1.05 (0.58-1.92) 1.50 (0.61-3.67) 0.63 (0.34-1.18) 0.95 (0.28-3.23) 
rs2424913_T 0.83 (0.46-1.52) 1.10 (0.45-2.69) 0.55 (0.29-1.03) 1.06 (0.34-3.34) 
rs2424932_A 0.72 (0.37-1.40) 0.94 (0.42-2.08) 1.11 (0.58-2.13) 1.28 (0.57-2.86) 
Haplotypea (>5%)     
TTG 1.06 (0.58-1.92) 1.12 (0.43-2.92) 0.61 (0.33-1.12) 1.28 (0.36-4.59) 
GCA 0.75 (0.39-1.45) 1.46 (0.61-3.48) 0.98 (0.53-1.84) 1.92 (0.81-4.57) 
GCG 0.81 (0.44-1.50) 12.86 (1.41-117.16) 1.25 (0.68-2.30) 1.76 (0.47-6.56) 
 
Associations have been evaluated both in dominant and recessive models.  
a rs1569686, rs2424913, rs2424932 
bAdjusted for source of tissue  
OR: Odds Ratios; CI: Confidence Intervals 
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Table 5.5. Association between genotypes and haplotypes of DNMT3b and LINE-1 
methylation level measured in tumor tissue 
 
Variant Adjacent tissue cohort  
 LINE-1 methylation level in tumor tissue 
 Coeff1 (95% CIs) Coeff2 (95% CIs) 
Genotype Dominant Recessive Dominant Recessive 
rs1569686_T -1.07 (-2.38 – 0.24) -2.11 (-4.72 – 0.50) -1.01 (-2.32 – 0.31) -2.20 (-4.80 – 0.40) 
rs2424913_T -0.91 (-2.21 – 0.39) 0.04 (-2.41 – 2.48) -0.83 (-2.14 – 0.48) 0.00 (-2.44 – 2.44) 
rs2424932_A 0.42 (-0.96 – 1.81) 1.77 (0.12 – 3.42) 0.42 (-0.96 – 1.80) 1.72 (0.07 – 3.37) 
Haplotypea (>5%)     
TTG -1.14 (-2.41 – 0.14) -1.44 (-4.17 – 1.29) -1.08 (-2.35 – 0.20) -1.40 (-4.13 – 1.32) 
GCA 0.06 (-1.28 – 1.40) 2.41 (0.66 – 4.17) 0.06 (-1.28 – 1.40) 2.32 (0.56 – 4.08) 
GCG 0.35 (-0.94 – 1.63) -0.87 (-3.60 – 1.87) 0.40 (-0.89 – 1.69) -1.12 (-3.87 – 1.63) 
 
Associations have been evaluated both in dominant and recessive models.  
a rs1569686, rs2424913, rs2424932 
Coeff1: adjusted for source of tissue; Coeff2: adjusted for source of tissue and year of diagnosis 
CI: Confidence Intervals 
 
 
 
Table 5.6. Analysis of association between genotypes and haplotypes of DNMT3b and 
Gleason score 
 
Variant 1980-biopsy cohort Adjacent tissue cohort 
 Gleason 8+ vs. <8 Gleason 8+ vs. <8 
 OR (95% CI)b OR (95% CI)b OR (95% CI)b OR (95% CI)b 
 Dominant Recessive Dominant Recessive 
Genotype     
rs1569686_T 1.39 (0.75-2.57) 1.23 (0.52-2.88) 1.06 (0.53-2.15) 0.50 (0.12-2.12) 
rs2424913_T 1.09 (0.59-2.01) 1.55 (0.62-3.90) 1.07 (0.53-2.15) 0.88 (0.23-3.33) 
rs2424932_A 1.24 (0.64-2.39) 0.59 (0.25-1.37) 1.13 (0.54-2.37) 0.58 (0.22-1.48) 
Haplotypea (>5%)     
TTG 1.24 (0.67-2.27) 1.40 (0.55-3.58) 1.06 (0.53-2.11) 0.69 (0.15-3.07) 
GCA 1.27 (0.66-2.43) 0.67 (0.27-1.65) 0.98 (0.48-2.00) 0.53 (0.19-1.50) 
GCG 0.74 (0.39-1.38) 0.54 (0.10-3.02) 1.36 (0.68-2.70) 2.19 (0.55-8.77) 
 
Associations have been evaluated both in dominant and recessive models.  
a rs1569686, rs2424913, rs2424932 
b Adjusted by source of tissue 
OR: Odds Ratios; CI: Confidence Intervals 
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Table 5.7. Analysis of association between genotypes and haplotypes of DNMT3b and 
mortality from prostate cancer 
 
Variant 1980-biopsy cohort Adjacent tissue cohort 
 HR (95% CI)b HR (95% CI)b HR (95% CI)b HR (95% CI)b 
 Dominant Recessive Dominant Recessive 
Genotype     
rs1569686_T 1.22 (0.83-1.80) 1.24 (0.72-2.13) 0.91 (0.49-1.70) 0.60 (0.14-2.57) 
rs2424913_T 1.02 (0.69-1.51) 1.37 (0.78-2.42) 0.71 (0.38-1.31) 1.14 (0.39-3.28) 
rs2424932_A 0.72 (0.48-1.09) 0.88 (0.50-1.55) 0.94 (0.49-1.82) 0.36 (0.13-1.00) 
Haplotypea (>5%)     
TTG 1.10 (0.75-1.61) 1.44 (0.80-2.59) 0.89 (0.48-1.63) 0.59 (0.14-2.50) 
GCA 0.84 (0.56-1.27) 0.79 (0.41-1.52) 0.84 (0.45-1.58) 0.47 (0.17-1.32) 
GCG 0.91 (0.62-1.35) 3.74 (1.33-10.55) 1.71 (0.91-3.19) 3.04 (1.16-7.94) 
 
Associations have been evaluated both in dominant and recessive models.  
a rs1569686, rs2424913, rs2424932 
b Adjusted by age at diagnosis, year of diagnosis, source of tissue.  
HR: Hazard Ratios; CI: Confidence Intervals 
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6. CONCLUSIONS 
 
In our ongoing project investigating the role of epigenetic alterations in prostate cancer, we 
found that promoter methylation of GSTP1 measured in a negative biopsy tissue is associated 
with prostate cancer diagnosis on a rebiopsy, especially for more aggressive tumors; predictive 
value of LINE-1 methylation level is less consistent and is reported only for low methylation 
levels.  
In prostate tumor tissue, gene-specific hypermethylation and global DNA hypomethylation 
coexist, expecially in high-grade tumors. We understood that LINE-1 hypomethylation, unlike 
gene-specific hypermethylation, is not an early event in prostate tumor: rather, it seems to be 
implicated in prostate cancer progression, but only in patients with more aggressive tumors. 
Low levels of LINE-1 methylation might be useful to distinguish into the group of the high-
risk prostate cancers only those leading to death. Our results also suggested that combinations 
of polymorphisms of the DNMT3b gene may have a noteworthy effect on mortality from 
prostate cancer and on gene-specific hypermethylation, suggesting that they could increase the 
expression of DNMT3b gene, thus.enhancing the enzyme production. The relationships 
between DNMT3b variants, methylation status in tumor and in NTAT, Gleason score and 
prostate cancer-specific mortality that we have assumed in our research are summarized in 
Figure 6.1 (below). 
Prostate cancer is a biologically and clinically heterogeneous disease, and new biomarkers to 
help avoid unnecessary biopsies and distinguish between aggressive and indolent disease are 
urgently requested. Epigenetic changes are hallmarks of prostate cancer and are associated with 
malignant initiation as well as tumor progression (Figure 6.1). DNA methylation is the most 
frequently studied epigenetic alteration in prostate cancer, and the diagnostic and prognostic 
potential of DNA methylation markers for this disease has been demonstrated in multiple 
studies. 
Identification of clinically relevant biomarkers remains a major challenge for prostate cancer 
management, as at present there are no prognostic tools that can accurately predict tumor 
progression at the time of diagnosis and improve the management of the patients. Currently, 
the best strategy could be the use of multi-parametric marker panels with inclusion of 
molecular markers into algorithms of existing clinicopathological parameters, thus potentially 
generating more robust tools for predicting prostate cancer outcome.  
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 Figure 6.1. Overall model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Red filled arrows indicate hypotetical causal relationships among currently unknown 
environmental exposures and the gene methylation status. Previously we evaluated the 
relationship among the hypermethylation of selected genes in tumor and non-neoplastic tumor 
adjacent to tumor (NTAT), tumor aggressiveness (Gleason score) and prostate cancer mortality 
[Richiardi et al., 2009; Richiardi et al., 2013]. In STUDY 2 we evaluated the relationship 
between LINE-1 hypomethylation in tumor and non-neoplastic tumor adjacent to tumor 
(NTAT), tumor aggressiveness (Gleason score) and prostate cancer mortality. 
Dashed red arrows indicate that other possible unmeasured variables (e.g. hypermethylation in 
genes other that those evaluated in this research) can potentially contribute to explain the 
association we found with aggressiveness and mortality. Yellow arrows (filled and dashed) 
indicate possible implication of the variants of the DNA-methyltransferase-3b gene in the 
methylation activity of the enzyme, and its possible relationship with prostate cancer mortality. 
In this model, the Gleason score represents an effect mediator, that captures the effects of the 
other variables.  
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7. FUTURE PERSPECTIVES 
 
We will expand the study on the potential prognostic value of methylation patterns in the 
tumour tissue and in the non-neoplastic tissue adjacent to tumor of prostate cancer patients 
within the “ProMort study”, a large case-control study that will involved prostate cancer cases 
and controls from the Swedish National Prostate Cancer Register. The overall aim of this 
project is to develop prognostic models for prostate cancer mortality in low- and intermediate- 
prostate cancer to improve the selection of patients who should be offered curative treatment or 
active surveillance. Cases will be prostate cancer patients with low- or intermediate-risk 
disease who died from the disease, while controls will be subjects with low- or intermediate-
risk prostate cancer who were alive at the time of death of the corresponding cases. 
Specifically, we will study a-priori specified methylation changes in the prostate tumour tissue 
and in NTAT in association with mortality from prostate cancer, to understand if these 
methylation markers, that have been previously identified in more heterogeneous and smaller 
series of patients, could have the predictive ability to further separate patients with 
intermediate Gleason score with respect to prognosis. 
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